Epigenetic regulation of CD14 in TRIF pathway in pulmonary alveolar macrophages of German Landrace pigs by Yang, Qin
 Institut für Tierwissenschaften, Abteilung Tierzucht und Tierhaltung 
der Rheinischen Friedrich-Wilhelms-Universität Bonn 
  
Epigenetic regulation of CD14 in TRIF pathway in  
pulmonary alveolar macrophages of German Landrace pigs 
 
Inaugural-Dissertation 
zur  
Erlangung des Grades 
 
Doktorin der Agrarwissenschaften 
(Dr. agr.) 
der 
Landwirtschaftlichen Fakultät 
der 
Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
von  
Qin Yang 
aus  
Mianning, Sichuan, China 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referent:  Prof. Dr. Karl Schellander 
Korreferent:    Prof. Dr. Dr. agr. Helga Sauerwein 
Tag der mündlichen Prüfung: 13. Mai 2016 
Erscheinungsjahr:    2016 
 
  
 
 
 
 
 
Dedicated to 
My beloved family 
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Epigenetic regulation of CD14 in TRIF pathway in pulmonary alveolar macrophages of 
German Landrace pigs 
 
Diseases of the respiratory system are a main problem in pig production. Pulmonary alveolar 
macrophages (PAMs) are key players to defend these respiratory diseases like lung 
inflammation caused by bacterial infection. Cluster of differentiation 14 (CD14) is the pattern 
recognition receptor (PRR) involved in the recognition of bacterial component 
lipopolysaccharide (LPS) through the MyD88-dependent and TRIF pathway of innate 
immunity. Gene expression regulation of CD14 and downstream genes may prevent LPS-
induced inflammation in pigs. However, epigenetic modulation on gene expression of CD14 
in response to infection is poorly understood. As a histone deacetylase (HDAC) inhibitor, 
sulforaphane (SFN) shows an anti-inflammatory activity and suppresses the DNA 
methylation. To identify the epigenetic changes of CD14 mediated with SFN in LPS-induced 
TRIF pathway, a PAMs model in vitro was investigated. For this, mRNA expression of CD14 
and downstream genes of TRIF pathway were quantified using qPCR. The cytokine level of 
tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β) were measured by enzyme - linked 
immunosorbent assay (ELISA). The protein level of NF-κB was analyzed by Western blot. In 
addition, gene expression of the epigenetic enzymes DNA methyltransferase-1 (DNMT1) and 
DNMT3a were quantified. Furthermore, the DNA methylation alterations of CD14 at 
promotor and gene body (CDS region) were analyzed using bisulfite sequencing in SFN and 
LPS treated PAMs. 
We found that CD14 gene expression was induced by 5 µg/ml LPS in time dependent manner. 
At time point 12 h, the gene expression of CD14 and downstream genes in TRIF pathway 
including TRIF, TRAF6, NFƳB, TRAF3, IRF7 and cytokines such as TNF-α, IL-1β, IL-6 and 
IFN-β were significantly induced by LPS. The LPS induced gene expression was suppressed 
by SFN in a dose dependent manner. The LPS-induced cytokine level of TNFα, IL-1β and 
NF-κB were also inhibited by SFN. Similarly, the DNMT3a mRNA expression was increased 
by LPS and down regulated by SFN at a dose of 5 µM. Furthermore, the bisulfite sequencing 
results presented that gene body methylation of CD14 was positively associated with gene 
expression of LPS treated PAMs and this methylation status was inhibited by SFN in a dose 
dependent manner. This in vitro study suggests that CD14 is involved in TRIF pathway 
including TRIF-TRAF6 and TRIF-TRAF3 pathway by LPS induction. Further, this LPS-
CD14 activation was suppressed by SFN via the epigenetic regulation of CD14 gene body 
methylation associated with DNMT3a.  
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This study provided novel insights into SFN-mediated epigenetic downregulation of CD14 
gene in LPS induced-TRIF pathway inflammation and may open new avenues of approaches 
to prevent and mitigate the LPS-induced inflammation in pigs. 
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Epigenetische Regulation von CD14 des TRIF-Signalwegs in Lungen 
Alveolarmakrophagen bei Schweinen der Deutschen Landrasse 
Krankheiten des Atmungssystems sind ein Hauptproblem in der Schweineproduktion. 
Pulmonale Alveolarmakrophagen (PAMs) spielen bei der Verteidigung des Körpers 
gegen Erkrankungen der Atemwege, wie Lungenentzündung, durch bakterielle 
Infektion eine Schlüsselrolle. Das „Cluster of differentation“ 14 (CD14) agiert als 
„pattern recognition receptor“ (PRR) und ist damit an der Identifizierung von 
bakteriellen Komponenten wie Lipopolysacchariden (LPS), durch die MyD88-
abhängigen und dem TRIF Signalweg der angeborenen Immunität, beteiligt. Die 
Regulation der Genexpression von CD14 und den nachgeschalteten Genen können die 
LPS-induzierte Entzündung verhindern. Allerdings, bisher jedoch sind epigenetische 
Modulationen von CD14 in Bezug auf Infektionen kaum untersucht. Als ein Histon-
Deacetylase (HDAC)-Inhibitor, zeigt Sulforaphan (SFN) eine entzündungshemmende 
Wirkung und unterdrückt die DNA-Methylierung. Um die epigenetischen 
Veränderungen von CD14 vermittelt durch SFN in LPS-induziertem TRIF Signalweg 
zu identifizieren, wurden PAMs in vitro untersucht. Hierzu wurden die mRNA-
Expression von CD14 und nachgeschalteten Gene des TRIF Signalwegs mit qPCR 
quantifiziert. Die Zytokinkonzentrationen von Tumornekrosefaktor-α (TNF) und 
Interleukin-1β (IL-1β) wurden mittels Enzym-linked Immunosorbent Assay (ELISA) 
gemessen. Der Proteingehalt von NF-κB wurde durch Western-blot bestimmt. Ebenfalls 
wurde die Genexpression der epigenetischen Enzyme DNA-Methyltransferase-1 
(DNMT1) und DNMT3a quantifiziert. Des Weiteren, wurde der DNA-
Methylierungsstatus von CD14 sowohl in der Promotor als auch in der intragenic 
Region (CDS Region) unter Verwendung von Bisulfit-Sequenzierung in SFN und LPS 
behandelten PAMs analysiert. Es konnte festgestellt werden, dass die Genexpression 
von CD14 durch 5 µg/ml LPS im Zeitverlauf angeregt wird. Zum Zeitpunkt 12 h nach 
LPS Behandlung zeigte sich ein signifikanter Genexpressionsunterschied von CD14 und 
nachgeschalteten Gene des TRIF Signalweges einschließlich TRIF, TRAF6, NFƳB, 
TRAF3, IRF7 und von Zytokinen wie TNF-α, IL-1β, IL-6 und IFN-ß. Der LPS- 
induzierte Genexpressionsunterschied wurde durch SFN dosisabhängig unterdrückt. 
Ebenfalls war das durch LPS-induzierte Zytokin-Level, einschließlich TNF, IL-1β und 
NF-κB, durch SFN gehemmt. Weiterhin konnte auch bei der mRNA-Expression von 
DNMT3a durch LPS eine erhöhte und durch SFN eine nach unten regulierte Expression 
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bei einer Dosis von 5µM festgestellt werden. Die Bisulfit-Sequenzierungsergebnisse der 
intragenic Region von CD14 ergab eine positive Assoziation mit der Gene-Expression 
von LPS-behandelten PAMs und dieser Methylierungsstatus wurde von SFN 
dosisabhängig gehemmt. Diese in vitro Studie legt nahe, dass CD14 nach LPS 
Behandlung an den TRIF Signalwegen, einschließlich TRIF-TRAF6 und TRIF-TRAF3 
beteiligt ist. Ferner wurde diese LPS-CD14-Aktivierung durch SFN über die 
epigenetische Regulation der Methylierung der CD14 intragenic Region assoziiert mit 
DNMT3a unterdrückt. Diese Studie gibt einen neuen Einblick in die SFN-vermittelte 
epigenetische Herunterregulation vom CD14-Gen in durch LPS induzierten TRIF 
Signalweg Entzündungen und kann neue Verfahrensweisen eröffnen die LPS-induzierte 
Entzündung bei Schweinen zu verhindern und zu mildern. 
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1 Introduction 
Inflammation is the body’s reaction to injuries including trauma, hypersensitivity and 
infection, which aims to defend against pathogens and repair tissue (Ferrero-Miliani et 
al. 2007, Moldoveanu et al. 2009). Unlike the adaptive immunity which needs more 
time for the defense against antigens, the innate immunity always takes a quick 
response to inflammatory-related stimulations (Sheu et al. 2013). Lipopolysaccharide 
(LPS) is the component of the outer membrane of gram-negative bacteria and one of the 
most predominant microbial stimulators of inflammation (Dobrovolskaia and Vogel 
2002). It activates the innate immune response in monocytes (Dobrovolskaia and Vogel 
2002), dendritic cells (DCs) (Dat et al. 2015) and macrophages (Zhao et al. 2015). 
Macrophages are phagocytes which develop and differentiate from tissue monocytes, 
with pivotal functions in host defense and inflammation (Ginhoux 2014, Gordon and 
Taylor 2005). In macrophages, LPS induces the production of pro-inflammatory 
cytokines including tumor necrosis factor-α (TNFα), interleukin1-β (IL-1β), IL-6 and 
IL-8 and anti-inflammation mediators such as IFN-a and IL-10 (Dobrovolskaia and 
Vogel 2002, Mosser and Edwards 2008, Rogler et al. 1998). Pulmonary alveolar 
macrophages (PAMs) or alveolar macrophages (AMs) reside in the pulmonary alveolus, 
constitute a vital component of the alveolar spaces and play a central role in pulmonary 
innate immunity (Hoppstadter et al. 2010, Sato-Nishiwaki et al. 2013). 
Cluster of differentiation 14 (CD14), a glycosyl-phosphatidylinositol (GPI)-linked 
protein is a pattern recognition receptor (PRR) which binds directly to LPS (Wright et 
al. 1990) and transfers LPS molecules in a co-expressed way to Toll-like receptor 4 
(TLR4) and lymphocyte antigen 96 (LY96, also know as MD-2) (da Silva Correia et al. 
2001). It enhances the inflammatory response and induced LPS-dependent production 
of IL-8 in vitro (He et al. 2014). CD14 was discovered as a myeloid differentiation 
antigen (Griffin et al. 1981) and human monocytes antigen (Todd et al. 1981) by 
reactivity of monoclonal antibodies (mAbs) depending on antigen-antibody reaction. 
There are two forms of CD14, the membrane CD14 (mCD14) (Todd et al. 1981) and the 
soluble CD14 (sCD14) (Maliszewski et al. 1985). It is already known that mCD14 is 
expressed in spleen macrophages and Kupffer cells in granuloma (Hancock et al. 1983, 
Ziegler-Heitbrock and Ulevitch 1993). CD14 knockdown in macrophages inhibited the 
secretion of inflammatory cytokines like IL-6 and LPS induced TNFα strongly. This 
suggested that CD14 was critical for LPS binding to macrophages (Ma et al. 2015). 
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CD14 is also expressed in AMs (Ziegler-Heitbrock and Ulevitch 1993) and it binds with 
LPS and delivers LPS to the TLR4-MD2 complex on AMs (Kuronuma et al. 2009). 
After LPS stimulation, CD14-TLR4 activates the myeloid differentiation primary-
response protein 88 (MyD88)-dependent and MyD88-independent pathway (TRIF 
pathway) (Akira and Takeda 2004). The TLR4-TRIF (TIR-domain-containing adaptor 
protein inducing interferon-β) interaction requires for the adaptor TRIF-related adaptor 
molecule (TRAM) and TRIF activates both TNF receptor associated factor 3 (TRAF3) 
and TRAF6 by a binding domain present on its N-terminus (Brown et al. 2011, Wang et 
al. 2001, Yamamoto et al. 2003b, Yamamoto et al. 2003a). The activation of TRAF6 or 
receptor-interacting serine/threonine-protein kinase (RIPK)-1 by TRIF initiates the NF-
κB signaling which is similar to the MyD88-dependent pathway (Qian and Cao 2013).  
While the activation of TRAF3 initiates the interferon (IFN) regulatory factor (IRF)-3 
through IKKi and TANK-binding kinase (TBK)-1, the phosphorylation of IRF3 induces 
the production of IFN-β  (Brown et al. 2011, Doyle et al. 2002). TRAF3 regulates the 
production of the anti-inflammatory cytokine IL-10 and the activation of the IFN 
(Hacker et al. 2006). It is well known that CD14 works in the LPS-MyD88 signaling 
(Haghparast et al. 2011, Jiao et al. 2013, Tachado et al. 2010, Tsai et al. 2011, Zhang et 
al. 2009) but its activation in the TRIF pathway is argumentative. It has been shown that 
LPS initiates TRIF signaling independent of CD14 (Watanabe et al. 2013) and CD14 is 
required for the TRIF-independent signaling (Jiang et al. 2005, Lloyd-Jones et al. 2008, 
Regen et al. 2011) through IRF3 (Roy et al. 2014). Thereby, CD14 may be involved in 
the TRIF pathway by directly binding with LPS. This LPS inducing CD14-TRIF 
pathway genes including CD14, TRIF-TRAF6 sub-pathway genes and TRIF-TRAF3 
sub-pathway genes may be further epigenetically regulated by DNA methylation. 
DNA methylation is one of the key epigenetic performers which interact with regulatory 
proteins and non-coding RNAs (Delcuve et al. 2009). It refers to the addition of methyl 
groups to the adenine or cytosine bases of the DNA (Plongthongkum et al. 2014). DNA 
methylation is associated with gene regulation (Wilson et al. 2014) by DNA 
methyltransferases (DNMTs) including DNMT1 and DNMT3. DNMT1 has 
maintenance methylation activity (Ronemus et al. 1996) and DNMT3 has the role in de 
novo methylation (Robertson et al. 2000). DNA methylation of gene promotor regions 
is associated with gene silencing (Bird 2002, Huang et al. 2014, Jones and Baylin 
2002). Oppositely, the gene body methylation is positively correlated with gene 
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expression in humans (Ball et al. 2009, Hellman and Chess 2007, Huang et al. 2014, 
Klose and Bird 2006, Laurent et al. 2010, Lister et al. 2009).  
Sulforaphane (SFN; 1-isothiocyanato-4-(methylsulfinyl)-butane), is a natural member 
of the isothiocyanate family which is mainly found in vegetables from consumed 
cruciferous vegetables such as broccoli, cabbage and kale (Juge et al. 2007, Meeran et 
al. 2010, Singh et al. 2005). It has anticancer (Ho et al. 2009, Meeran et al. 2010, Singh 
et al. 2005, Xiao et al. 2009), anti-inflammatory (Ko et al. 2013), antioxidant and 
antidiabetic (de Souza et al. 2012) effects. It has been shown that SFN also leads to the 
demethylation of gene promoter region. SFN treatment caused the demethylation of the 
first 5 CpGs in the promoter region of the nuclear factor erythroid-derived 2-like 2 
(Nrf2) gene, thereby it increased messenger RNA (mRNA) and protein expression of 
Nrf2 and Nrf2 downstream target genes, while it decreased the protein levels of 
DNMT1 and DNMT3a (Zhang et al. 2013).  
Reports on CD14 function in TRIF pathway are controversial. Furthermore, the CD14 
gene expression regulation which may be controlled by the epigenetic factor SFN has 
not been shown. In this study, we have performed the first epigenetic analysis of 
porcine CD14 gene with the histone deacetylase HDAC inhibitor SFN, using LPS 
treated PAMs of German Landrace (GL) pigs. The aim of this study is to investigate the 
potential of SFN suppression for CD14 gene expression in TRIF pathway through the 
epigenetic modification in pig PAM cells.
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2 Literature review 
2.1 Inflammation and innate immunity  
Inflammation is the body’s reaction to injuries and stimulations including trauma, 
hypersensitivity and infection, which aim to defend the body against pathogens and repair 
tissue (Ferrero-Miliani et al. 2007, Moldoveanu et al. 2009). Lung inflammation is the 
vigorous response to the aggressors including pollutants, irritants, allergens, toxins and 
pathogens which easily may reach to lung because it supplies a huge surface for gas 
exchange and pathogen exposure (Moldoveanu et al. 2009). 
Innate immunity and adaptive immunity are the two major defenses of the host against 
micro-bacterial, viral, or other antigenic stimulations. Unlike the adaptive immunity which 
needs time to against the antigen, the innate immunity reaction always takes quick 
response to the inflammatory or antigen-related stimulation (Sheu et al. 2013), thereby it 
first identifies the specific antigens and then launches inflammatory cells to target that 
designated antigens (Moldoveanu et al. 2009).  
2.2 Cells in the innate immune response 
As cells of the innate immune system, mast cells (MCs) not only have the role of inducing 
inflammation by producing pro-inflammatory mediators, but also can act as key regulators 
of tolerance (Jungraithmayr 2015). Phagocyte such as macrophage, neutrophil and 
dendritic cell displays an early and crucial event in host defenses against pathogens 
(Henneke and Golenbock 2004). Basophil is an innate immune cell which has expression 
of a functional TLR2 receptor, while eosinophil is the innate immune inducer which lead 
the production of cytokines including transforming growth factor-β (TGF-β), interleukin 
(IL)-3, IL-4, IL-5, IL-8, IL-10, IL-12, IL-13, IL-16, IL-18 and tumor necrosis factor 
(TNF)-α (Stone et al. 2010). Natural killer cells (NKs) are also important contributors to 
innate defense against a number of different infectious agents (Biron et al. 1999). 
2.3 Pulmonary alveolar macrophages and inflammation 
Macrophages are phagocytes which developed and differentiated from monocytes in the 
tissues, with pivotal functions in development, tissue remodeling, repair or homeostasis, 
host defense and inflammation (Ginhoux 2014, Gordon and Taylor 2005). They are 
antigen-presenting cells since they express the major histocompatibility complex (MHC) 
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class II molecules, therefore they work not only in innate immunity but also in adaptive 
immunity (Hoppstadter et al. 2010). Macrophages are the main source of cytokines, 
chemokines and other inflammatory mediators that disseminate or inhibit the immune 
response (Moldoveanu et al. 2009). Furthermore, macrophages can secret quite a few 
cytokines including the pro-inflammatory cytokines such as TNF, IL-1, IL-6 and IL-8 and 
anti-inflammatory mediators such as IL10, thus they play a crucial role in inflammation 
(Mosser and Edwards 2008, Rogler et al. 1998).  
Pulmonary alveolar macrophages (PAMs), or alveolar macrophages (AMs) are a type of 
macrophages, which reside in the pulmonary alveoli (Fig. 1) (Wissinger et al. 2008). They 
constitute a vital component of the alveolar spaces and play a central role in pulmonary 
innate immunity (Hoppstadter et al. 2010, Sato-Nishiwaki et al. 2013).  
 
Fig. 1 PAMs are located in the alveoli (Wissinger et al. 2008, modified) 
2.4 Pathogen recognition by innate immunity 
Unlike the adaptive immunity, innate immunity has a role in the nonspecific recognition of 
pathogens, by which it is activated via pathogen associated molecular patterns (PAMPs) 
linking to pattern recognition receptors (PRRs) (Maciejewska Rodrigues et al. 2009). 
PAMPs are derived from microorganisms such as bacteria, fungi, parasites and viruses. 
Bacteria include gram-negative bacteria lipopolysaccharide (LPS), gram-positive bacteria 
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peptidoglycan (PG), lipoteichoic acid (LTA), flagellin and C-phosphate-G (CpG)-DNA. 
Viruses comprise DNA, double-stranded RNA (dsRNA) and single-stranded RNA 
(ssRNA) (Akira et al. 2006). They are recognized by Toll-like receptors (TLRs) and other 
PRRs, such as nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), 
retinoid acid-inducible gene I (RIG-I)-like receptors (RLRs) and absent in melanoma 2 
(AIM2) like receptors (ALRs) (Akira et al. 2006, Creagh and O'Neill 2006, Janeway and 
Medzhitov 2002, Tang et al. 2012). Several classes of PRRs, including TLRs and 
cytoplasmic receptors like NLRs and RLRs, recognize different microbial components and 
activate immune cells directly (Akira et al. 2006).  
2.4.1 LPS 
Lipopolysaccharide (LPS) endotoxin is an outer membrane component of gram-negative 
bacteria and one of the most predominant microbial stimulator of inflammation 
(Dobrovolskaia and Vogel 2002). Peripheral stimulation of the innate immune system with 
LPS causes an exaggerated neuro-inflammatory response in aged BALB/c mice (Henry et 
al. 2009). The structure of LPS includes a hydrophobic domain named lipid A, a distal 
polysaccharide (O-antigen) and a core oligosaccharide (Fig. 2) (Raetz and Whitfield 2002). 
LPS activates the innate immune response with monocytes (Dobrovolskaia and Vogel 
2002), dendritic cells (DCs) (Dat et al. 2015) and macrophages (Zhao et al. 2015). In 
macrophages, LPS induces the production of inflammation cytokines, such as TNF-α and 
IL1-β (Beutler and Cerami 1988, Carson et al. 2011, Dinarello 1991) and anti-
inflammation mediator IL-6 (Dobrovolskaia and Vogel 2002). 
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Fig. 2 LPS structure and membrane structure of E. coli (Raetz and Whitfield 2002) 
(PPEtN: phosphate-pyrophosphorylethanolamine, Kdo: 3-deoxy-D-manno-oct-2-ulosonic 
acid, MDO: membrane-derived oligosaccharides) 
2.4.2 TLRs  
TLRs are type I transmembrane proteins. They have three parts with ectodomains, 
transmembrane domains and intracellular toll-IL-1 receptor (TIR) domains. The 
ectodomains contain leucine-rich repeats (LRRs) that mediate the recognition of PAMPs,  
while the TIR domain is the part which is required for downstream signal transduction 
(Kawai and Akira 2010). So far, 12 members of the TLRs family have been identified in 
mammals (Akira et al. 2006), while 10 functional TLRs have been identified in humans 
(Kawai and Akira 2010). TLRs recognize PAMPs including proteins, lipids (TLR1, TLR2 
and TLR6), lipoproteins and nucleic acids (TLR8 and TLR9) derived from a wide range of 
microbes such as viruses, bacteria, fungi and parasites (Akira et al. 2006, Kawai and Akira 
2010). 
Based on their cellular localization and respective PAMP ligands, TLRs can be divided 
into 2 subfamilies, one is composed of TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 
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which are expressed on cell surfaces and recognize mainly microbial membrane 
components such as lipids, lipoproteins and proteins; the other one is composed of TLR3, 
TLR7, TLR8 and TLR9 which are expressed only in intracellular vesicles such as the 
lysosomes, endosomes, endolysosomes and endoplasmic reticulum (ER),  where they 
recognize microbial nucleic acids (Kawai and Akira 2010). 
TLR1 recognizes the microbial components of triacyl lipopeptides from the species of 
bacteria and mycobacteria (Table 1) (Akira et al. 2006). TLR2 can recognize several 
microbial components including diacyl lipopeptides (mycoplasma), triacyl lipopeptides 
(bacteria and mycobacteria), LTA (group B Streptococcus), peptidoglycan (PG, gram-
positive bacteria), porins (Neisseria), lipoarabinomannan (mycobacteria), zymosan 
(Saccharomyces cerevisiae), phospholipomannan (Candida albicans), 
glucuronoxylomannan (cryptococcus neoformans), tGPI-mutin (Trypano-soma), 
hemagglutinin protein (measles virus) (Table 1) (Akira et al. 2006). TLR4, the typical 
member of the TLR family which is the only receptor utilizing all four TIR-domain-
containing adaptors (Kagan and Medzhitov 2006). It was the first PRR discovered to be 
expressed in mammalian innate immune cells (Medzhitov and Janeway 1997). Two 
pathways including the myeloid differentiation primary-response protein 88 (MyD88)-
dependent and MyD88-independent pathways are activated when TLR4 is stimulated with 
LPS (Akira and Takeda 2004). 
Table 1 TLR recognition of microbial components (Akira et al. 2006) 
Microbial components Species TLR usage 
Bacteria   
LPS Gram-negative bacteria TLR4 
Diacyl lipopeptides Mycoplasma TLR6/TLR2 
Triacyl lipopeptides Bacteria and mycobacteria TLR1/TLR2 
LTA Group B Streptococcus TLR6/TLR2 
Peptidoglycan Gram-positive bacteria TLR2 
Porins Neisseria TLR2 
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Lipoarabinomannan Mycobacteria TLR2 
Flagellin Flagellated bacteria TLR5 
CpG-DNA Bacteria and mycobacteria TLR9 
ND (not determined) Uropathogenic bacteria TLR11 
Fungus   
Zymosan Saccharomyces cerevisiae TLR6/TLR2 
Phospholipomannan Candida albicans TLR2 
Glucuronoxylomannan Cryptococcus neoformans TLR2 and TLR4 
Parasites   
tGPI-mutin Trypanosoma TLR2 
Glycoinositolphospholipids Trypanosoma TLR4 
Hemozoin Plasmodium TLR9 
Profilin-like molecule Toxoplasma gondii TLR11 
Viruses   
DNA Viruses TLR9 
dsRNA Viruses TLR3 
ssRNA RNA viruses TLR7 and TLR8 
Envelope proteins RSV, MMTV TLR4 
Hemagglutinin protein Measles virus TLR2 
Host   
Heat-shock protein 60, 70  TLR4 
Fibrinogen  TLR4 
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2.4.3 The TLR signaling pathway 
Depending on ligand stimulation, TLRs attract different adaptor proteins including 
MyD88, myD88-adaptor-like (Mal), TIR-domain-containing adaptor protein inducing 
IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM) by TIR-TIR interactions (Qian 
and Cao 2013). All TLRs, with the exception of TLR3, activate the MyD88-dependent 
signaling pathway by utilizing MyD88 while TLR4 and TLR3 initiate the TRIF-dependent 
(MyD88-independent pathway) signaling pathway (Qian and Cao 2013). The whole TLR 
signaling pathway is shown in Fig. 3. 
(http://www.kegg.jp/kegg-bin/highlight_pathway?scale=1.0&map=map04620&keyword=myd88) 
 
Fig. 3 TLR signaling pathway (KEGG 20150205) 
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2.4.3.1 The MyD88-dependent pathway 
The TLR4/MyD88 signaling pathway is primarily used to induce the expression of pro-
inflammatory cytokines (Brown et al. 2011). MyD88 activates IL-1 receptor-associated 
kinase (IRAK)-1 though the interaction with IRAK-4 by the death domain part of IRAK-4. 
Then the activation of TNF receptor associated factor (TRAF)-6 is promoted with other E2 
ubiquitin protein ligases which activate a compound containing TGF-β-activated kinase 
(TAK)-1, TAK1-binding protein (TAB)-1, TAB-2 and TAB-3 (Brown et al. 2011, Cao et 
al. 1996, Chen 2005, Li et al. 2000, Li et al. 2002, Muzio et al. 1997). The TAK1/TABs 
complex induces the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) signaling pathway by activating IƳB kinase (IKK) and the mitogen-activated protein 
kinases (MAPK) signaling pathway by Jun amino-terminal kinase (JNK) (Wang et al. 
2001). 
2.4.3.2 The TRIF-dependent pathway 
The TRIF-dependent (MyD88 independent) pathway is initiated by the TLR3 and TLR4 
(Qian and Cao 2013). The TLR4-TRIF interaction requires for the adaptor TRAM and 
TRIF activates both TRAF3 and TRAF6 by a binding domain present on its N-terminus 
(Brown et al. 2011, Wang et al. 2001, Yamamoto et al. 2003a, Yamamoto et al. 2003b). In 
spite of the similar structure, TRAF3 and TRAF6 have different functions in the TRIF 
signaling pathway (Hacker et al. 2006). The activation of TRAF6 or receptor-interacting 
serine/threonine-protein kinase (RIPK)-1 by TRIF initiates the nuclear factor 'kappa-light-
chain-enhancer' of activated B-cells (NF-κB) signaling which is similar to the MyD88-
dependent pathway (Qian and Cao 2013). While the activation of TRAF3 initiates the 
interferon (IFN) regulatory factor (IRF)-3 through IKKi and TANK-binding kinase (TBK)-
1, the phosphorylation of IRF3 induces the production of IFN-β (Brown et al. 2011, Doyle 
et al. 2002). TRAF3 regulates the production of anti-inflammatory cytokine IL-10 and the 
activation of the IFN (Hacker et al. 2006). The TRIF pathway is shown in Fig. 4 (KEGG 
http://www.kegg.jp/kegg-bin/highlight_pathway?scale=1.0&map=map04620&keyword=myd88). 
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Fig. 4 TRIF signaling pathway (KEGG 20150205 with modification) 
2.5 CD14 gene and its function  
2.5.1 Molecular structure, forms and distribution of CD14 
Cluster of differentiation 14 (CD14) was discovered as a myeloid differentiation antigen 
(Griffin et al. 1981) and human monocytes antigen (Todd et al. 1981) by reactivity of 
monoclonal antibodies (mAbs) depending on antigen-antibody reaction. CD14 is a 53-55 
kDa glycoprotein (Gregory and Devitt 1999) with 356 amino acids (Goyert et al. 1988), it 
contains the leucine-rich repeats which are incorporated into the plasma membrane via a 
glycosyl-phosphatidylinositol (GPI) anchor (Gregory and Devitt 1999). The CD14 gene is 
located on chromosome 5q 23-q31 in human (Goyert et al. 1988) and chromosome 18 in 
mouse (Ferrero et al. 1990). In addition to human and mouse, CD14 gene was identified in 
other species. Bovine CD14 gene encodes 373 amino acids and the coding sequence is 
separated by a 90 nt intron (Ikeda et al. 1997). In rat, CD14 gene contains 883 bp of 5′-
flanking region, a 93 bp exon-1, an 87 bp intron followed after the ATG translation start 
codon and a 377 bp partial exon-2 (Liu et al. 2000). The porcine CD14 gene is located to 
chromosome 2q21 which includes two exons and a short intron (80 bp) following after the 
ATG translation start codon (Qiu et al. 2007). 
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CD14 exists in two forms, the membrane CD14 (mCD14) (Todd et al. 1981) and the 
soluble CD14 (sCD14) (Maliszewski et al. 1985). mCD14 is expressed in spleen 
macrophages and kupffer cells in granuloma (Hancock et al. 1983, Ziegler-Heitbrock and 
Ulevitch 1993). It is also expressed in alveolar macrophages and microglia cells (Ziegler-
Heitbrock and Ulevitch 1993). sCD14 was detected in cellular supernatant of monocytes 
and normal plasma (Maliszewski et al. 1985). The porcine CD14 gene was expressed in 
various tissues, such as spleen, liver, thymus, skeletal muscle and white matter (Qiu et al. 
2007).  
2.5.2 Functional properties of CD14 
2.5.2.1 CD14 as biomarker of disease 
CD14 is an acute phase inflammatory biomarker. In older adults, it predicts cardiovascular 
disease. It also strongly and independently predicts all-cause mortality in older adults 
(Reiner et al. 2013). Periodontitis, a chronic infectious disease of tooth supporting tissues 
which is leading to inflammation and loosing teeth subsequently, is associated with 
elevated levels of sCD14 (Nicu et al. 2009). sCD14 is a marker of disease activity in 
Crohn's disease (CD) (Lakatos et al. 2011). It is also a potential marker for pneumonia in 
children (Marcos et al. 2010). Microglia-derived sCD14 is a candidate cerebrospinal fluid 
biomarker for Alzheimer's disease (AD) and Parkinson's disease (PD) (Yin et al. 2009). It 
is also shown that the sCD14 level is associated with inflammation and protein-energy 
wasting in hemodialysis patients (Raj et al. 2009). sCD14 was higher in unstimulated 
whole saliva (UWS) and it was used as potential salivary biomarker for oral lichen planus 
(OLP) and burning mouth syndrome (BMS) (Srinivasan et al. 2008). It’s suggested that the 
elevated sCD14 concentration may be one of the host-response components of the 
periodontal disease clinical manifestations (Isaza-Guzman et al. 2008). Inhibition of CD14 
may be a novel treatment strategy in melioidosis because it plays a detrimental role in the 
host response against burkholderia pseudomallei although it is involved in the recognition 
of burkholderia pseudomallei by innate immune cells (Wiersinga et al. 2008). Bottema et 
al. indicates that atopy is importantly influenced by CD14 in interaction with pet exposure 
at the age of 4 and 8 years childen (Bottema et al. 2008). 
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2.5.2.2 CD14 is responsible for immunity and TLR activities 
Soluble CD14 is associated with human dendritic cell cytokine production and increased T 
cell responses (Liu et al. 2012). CD14-159C/T could effect the T cell-mediated immunity 
in extensively burned patients (Dong et al. 2009). The CD14-159C>T polymorphism is 
associated with soluble CD14 gene expression, which might influence the balance of pro- 
and anti-inflammatory immune responses in healthy term neonates (Hartel et al. 2008). 
CD14 expression in tonsils and adenoids implies that CD14 takes part in an important 
immunological sentinel function in the innate immunity of the upper airway (Ben-Yaakov 
et al. 2010). 
CD14 plays a role in the stimulation of TLRs and it acts as a co-receptor for endosomal 
TLR activation (Baumann et al. 2010). CD14-mediated TLR activation might be related 
with the cardiovascular and metabolic complications of obesity (Roncon-Albuquerque et 
al. 2008). CD14 was necessary for the microbe-induced endocytosis of TLR4 while CD14 
controls the trafficking and signalling functions of TLR4. This innate immune trafficking 
cascade illustrates how pathogen detection systems operate to induce both membrane 
transport and signal transduction (Zanoni et al. 2011). CD14 gene expression is critical for 
TLR2-mediated recognition of LTA in human peripheral blood (Bunk et al. 2010). CD14 
is responsible for the internalization of TLR2 ligand fibroblast stimulating ligand-1(FSL-1) 
via the clathrin-dependent endocytic pathway (Shamsul et al. 2010). CD14 is a co-receptor 
of TLR7 and TLR9, it is required for TLR7- and TLR9-dependent induction of pro-
inflammatory cytokines in vitro and for TLR9-dependent innate immune responses in mice 
(Baumann et al. 2010). TLR9 immune response of A, B and C-classes oligodeoxy-
nucleotides was upregulated by CD14 (Weber et al. 2012). Taken all together, the CD14 
function in the TLRs can be explained in three panels: (1) CD14 activates NF-κB -
dependent cytokine production with low-LPS doses challenge; (2) CD14 promotes TLR4 
endocytosis and type-I IFN expression in TRIF pathway; (3) CD14 has the role to lead to 
the activation of nuclear factor of activated T-cells, cytoplasmic (NFATc) transcription 
factor family members (Fig. 5) (Zanoni and Granucci 2013).  
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Fig. 5 CD14 fundamental functions in the TLRs (Zanoni and Granucci 2013) 
2.5.3 CD14 is required for LPS - induced TRIF pathway 
CD14 is the PRR which binds directly to LPS (Wright et al. 1990) and transfers LPS 
molecules in a co-expressed way to TLR4 and lymphocyte antigen 96 (LY96 or MD-2) (da 
Silva Correia et al. 2001). It is shown that CD14 is critical for LPS binding to 
macrophages, CD14 knockdown in macrophages inhibited the secretion of inflammatory 
cytokines including IL-6 and TNFα induced by LPS (Ma et al. 2015). CD14 enhanced the 
inflammatory response and LPS-dependent production of IL-8 induced by type 1 pili 
enterotoxigenic E. coli (ETEC) in vitro (He et al. 2014). It has been well known that CD14 
is involved in the LPS-MyD88 signaling pathway (Haghparast et al. 2011, Jiao et al. 2013, 
Tachado et al. 2010, Tsai et al. 2011, Zhang et al. 2009) but its involvement in the TRIF 
pathway is argumentative. It was shown that LPS initiates the TRIF pathway independent 
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of CD14 (Watanabe et al. 2013), but evidence also displayed that CD14 is required for the 
TRIF-independent signaling (Jiang et al. 2005, Lloyd-Jones et al. 2008, Regen et al. 2011) 
through IRF3 (Roy et al. 2014). Thereby, it is not only important for the MyD88-
dependent pathway to express TNFa, but is also required for the TRIF pathway to mediate 
IFNs expression (Jiang et al. 2005) via regulation of TLR4 endocytosis and facilitation of 
TRIF-mediated signal transduction (Zanoni et al. 2011).  
2.6 Epigenetics 
Epigenetics is the study of mitotically and/or meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence (Russo et al. 1996). 
The epigenetic mechanisms regulate all biological processes including genome 
reprogramming during early embryogenesis and gametogenesis, cell differentiation and 
maintenance of a committed lineage (Delcuve et al. 2009). Key epigenetic performers 
are DNA methylation, RNA interference and histone modifications which interact with 
regulatory proteins and non-coding RNAs (Fig. 6) (Delcuve et al. 2009, Kim et al. 
2011).  
 
Fig. 6 Scheme of epigenetic mechanisms (Kim et al. 2011) 
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2.6.1 DNA Methylation  
DNA methylation refers to the addition of methyl groups to the adenine or cytosine bases 
of DNA (Plongthongkum et al. 2014) and is associated with gene regulation (Wilson et al. 
2014). It has inhibitory influence on gene expression by recruitment of methyl binding 
proteins, interference with transcription factor binding and the establishment and 
maintenance of an oppressive chromatin structure (Curradi et al. 2002, Havlis and Trbusek 
2002, Liu et al. 2004). The most common mark of DNA methylation is the 
5-methylcytosine (5mC) (Plongthongkum et al. 2014). Most of the DNA methylation 
analysis work in animals has focused on 5-methylcytosine (5mC) in the CpG sequence 
context. In vertebrate genomes, more than half of the genes contain short (approximately 1 
kb) CpG-rich regions known as CpG islands (CGIs) (Jones 2012). 
DNA methylation can occur in the promoter and gene body regions of genes. DNA 
methylation of gene promotor is associated with gene silencing (Bird 2002, Huang et al. 
2014, Jones and Baylin 2002), oppositely, gene body methylation is positively correlated 
with gene expression in humans (Ball et al. 2009, Hellman and Chess 2007, Huang et al. 
2014, Klose and Bird 2006, Laurent et al. 2010, Lister et al. 2009). 
2.6.1.1 Gene body methylation 
Gene body methylation is the DNA methylation of transcription units (Sarda et al. 2012). It 
occurs not only in human genomes but also in the genomes of animal and plant species 
(Sarda et al. 2012, Yu et al. 2015). Recent researches show the increasing support of the 
gene body methylation as the ancestral pattern of DNA methylation in animal genomes 
(Feng et al. 2010, Zemach et al. 2010). Although the promoter DNA methylation is known 
as a silencing mechanism, the gene body has recently been recognized as a major 
mechanism for regulating gene expression in many tissues (Baylin and Jones 2011). Unlike 
the negative effect of promotor methylation on gene expression, gene body methylation 
displays a positive role (Huang et al. 2014). The strongest correlation between the age-
related changes in gene expression and methylation is not confined to the promoter region; 
oppositely, the high densities of hypo-methylated CpG-rich regions crossing the gene body 
are preferentially associated with gene downregulation (Yu et al. 2015). It is displayed that 
methylation in the gene body region does not prevent transcription elongation in genome-
wide approaches (Ball et al. 2009). However, the underlying mechanisms of gene body 
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methylation in regulating gene expression and the functional roles of gene body 
methylation is still not clear. 
2.6.1.2 DNA modification enzymes 
DNA methyltransferases (DNMTs) are the family of enzymes which catalyze the methyl 
reaction via transferring a methyl group from S-adenosylmethionine to the 5 position of 
cytosine on CpG dinucleotides (Arand et al. 2012, Teerawanichpan et al. 2004). DNMT1 
was the first discovered DNMTs in mammals (Bestor 2000), then DNMT2 (Yoder and 
Bestor 1998) and DNMT3 (DNMT3a and DNMT3b) families were found respectively 
(Okano et al. 1998). It’s has been shown that DNMT1 class has maintenance methylation 
activity in vivo (Ronemus et al. 1996), DNMT2 class has only a methyltransferase domain 
therefore it lacks significant role in DNA methylation (Okano et al. 1998) while DNMT3 
class contributes the role in de novo methylation (Robertson et al. 2000).  
In addition to DNMTs, a class of enzymes named ten-eleven translocation (TET) including 
TET1, TET2 and TET3 have been discovered to produce epigenetic modifications like 
5-carboxylcytosine (5caC), 5-formylcytosine (5fC) and 5-hydroxymethylcytosine (5hmC) 
(Plongthongkum et al. 2014).  
2.6.1.3 Bisulfite sequencing 
Bisulfite genomic sequencing is a effective technique to discern the 5-methylcytosine 
position for the accurate mapping of methylation sites on individual DNA molecules by 
using sodium bisulfite to convert un-methylated cytosine residues to uracil with a very 
small amounts of genomic DNA (gDNA) (Clark et al. 1994). The technical steps of 
bisulfite sequencing are (1) bisulfite conversion of gDNA, (2) polymerase chain reaction 
(PCR) by using bisulfite PCR primers for bisulfite-converted DNA and (3) direct 
sequencing or cloning of the purified bisulfite PCR and then sequencing (Frommer et al. 
1992, Liu et al. 2004) (Fig. 7). 
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Fig. 7 Bisulfite genomic sequencing (Liu et al. 2004) 
2.6.2 Histone modifications 
Histone modification is another key epigenetic factor which is typically controlled by the 
dynamic processes including histone acetylation and histone deacetylation (HDAC) 
regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
respectively (Meeran et al. 2010). Histone acetylation like acetylation of histone H3 and   
acetylation of histone H4 causes the transcriptional activation throughout chromatin 
remodeling. Conversely, histone deacetylation results in transcriptional silencing (Meeran 
et al. 2010). HDACs are enzymes that eliminate the acetyl modification from histones 
(Delcuve et al. 2009). HDAC inhibitors induce the HAT co-activator complexes to transfer 
acetyl groups to lysine residues in histones, therefore an open chromatin structure which 
facilitates the binding of transcription factors to gene promoters for regulation of gene 
expression (Meeran et al. 2010, Murakami et al. 2005, Struhl 1998). In addition to 
acetylation, histones also have reversible post-translational modifications (PTMs) 
including ubiquitination, phosphorylation, adenosine diphosphate (ADP) - ribosylation and 
methylation (Kouzarides 2007).  
2.6.3 RNA interference 
MicroRNAs (miRNAs) are small RNA molecules, about 22 nucleotides long, that can 
suppress their target gene expression post-transcriptionally. They were described first in 
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Caenorhabditis elegans in 1993. miRNAs have been shown to inhibit translation or 
decrease mRNA stability by binding to specific sites usually in the 3’ untranslated region 
(3′UTR) of target messages, thus providing another way of gene expression controlling 
(Kim et al. 2011). 
2.7 SFN as a regulator of anti-inflammation and epigenetics 
Sulforaphane (SFN; 1-isothiocyanato-4-(methylsulfinyl)-butane), a naturally occurring 
member of the isothiocyanate family mainly found in cruciferous vegetables such as 
broccoli, broccoli sprouts, cauliflower, radish, cabbage and kale (Juge et al. 2007, Meeran 
et al. 2010, Singh et al. 2005), has anticancer (Ho et al. 2009, Meeran et al. 2010, Singh et 
al. 2005, Xiao et al. 2009), anti-inflammatory (Ko et al. 2013), antioxidant and antidiabetic 
(de Souza et al. 2012) effects.  
The anticancer function of SFN is considered to be associated to the inducing of phase-II 
enzymes of xenobiotic transformation or detoxifying and transcription increment of tumor 
suppressor proteins perhaps by inhibitory effects on histone deacetylase (Brandenburg et 
al. 2010). It was shown that SFN also can lead to the demethylation of gene promoter 
region. SFN treatment caused the demethylation of the first 5 CpGs in the promoter region 
of the nuclear factor erythroid-derived 2-like 2 (Nrf2) gene, thereby it increased messenger 
RNA (mRNA) and protein expression of Nrf2 and Nrf2 downstream target genes, while it 
decreased the protein levels of DNMT1 and DNMT3a (Zhang et al. 2013).  
SFN has been shown to have an anti-inflammatory role. SFN regulates LPS-induced innate 
immune responses of monocyte-derived dendritic cells (moDCs) in pigs (Qu et al. 2015). It 
modulates TLR4 activation and inhibits LPS-induced inflammatory responses (Koo et al. 
2013). Functions of SFN in the modulation of TLR4 signaling have been investigated in 
different cell lines. SFN reduced LPS-induced TNF-α expression in macrophage cells 
(Youn et al. 2010). It also suppressed NFκB in LPS stimulated RAW macrophages (Heiss 
et al. 2001) and endothelial cells (Liu et al. 2008). SFN and nobiletin (NBN) inhibit 
synergistically LPS-induced inflammation in RAW 264.7 cells (Guo et al. 2012). It has 
been shown that SFN suppressed LPS-induced inducible nitric oxide synthase (iNOS), 
cyclooxygenase-2 (COX-2) and TNF-α expression in mouse macrophages (Heiss et al. 
2001). 
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2.8 Hypothesis and Objectives 
Hypothesis:  
LPS-induced CD14 expression can be modified by SFN through epigenetic mechanisms in 
the TRIF pathway in pulmonary alveolar macrophages of German Landrace pigs  
Objectives: 
(1) To investigate the effect of LPS on CD14 gene expression in PAMs of German 
Landrace pigs 
(2) To find out the epigenetic effect of SFN on LPS-induced CD14 expression in 
PAMs of German Landrace pigs 
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3 Material and methods 
3.1 Material 
3.1.1 Reagents  
Chemical Cat.no. Manufacturer/Supplier 
Ketamin 98046 
Pharmazeutische, Handelgesellschaft 
GmbH, Garbsen - Berenbostel 
T61 03542 
Pharmazeutische Handelgesellschaft 
GmbH, Garbsen - Berenbostel 
Meliseptol®  1110493 Labomedic GmbH, Bonn, Germany 
NaCl P029.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Na2HPO4.2H2O T877.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
KCl 6781.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
KH2PO4 3904.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
DPBS (1×) 14190-094 
Life Technologies GmbH, Darmstadt, 
Germany 
Fungizone® antimycotic 15290-026 
Life Technologies GmbH, Darmstadt, 
Germany 
Penicillin-streptomycin 
(10,000 U/ml) 
15140-122 
Life Technologies GmbH, Darmstadt, 
Germany 
NH4Cl K298.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
KHCO3 P748.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
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EDTA 8043.2 Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
RPMI 1640 medium 61870-044 
Life Technologies GmbH, Darmstadt, 
Germany 
FBS 10270-106 
Life Technologies GmbH, Darmstadt, 
Germany 
Gentamicine (10 mg/ml) 15710-049 
Life Technologies GmbH, Darmstadt, 
Germany 
Trypan blue stain (4%) 93595 Sigma-Aldrich (Fluka), St. Louis, USA 
LPS-EB  tlrl-3pelps InvivoGen, California, USA 
R,S-sulforaphane  4478-93-7 Biomol GmbH, Hamburg, Germany 
DMSO (≥ 99.9%) 154938 Sigma-Aldrich, St. Louis, USA 
Anti-CD163 antibody MCA2311F 
Bio-Rad Laboratories GmbH, München, 
Germany 
WST-1 Cell Proliferation 
Assay Kit 
10008883 Biomol GmbH, Hamburg, Germany 
AllPrep®DNA/RNA/Potein 
Mini Kit 
80004 Qiagen GmbH, Hilden, Germany 
First Strand cDNA 
Synthesis Kit 
K1612 
Thermo Fisher Scientific Inc. St. Leon-
Roth, Germany 
iTaqTM Universal SYBR® 
Green Supermix 
172-5120 
Bio-Rad Laboratories GmbH, München, 
Germany 
EZ DNA Methylation-
DirectTM Kit  
D5020 
Zymo Research Europe GmbH, Freiburg, 
Germany 
Ethanol (≥ 99,8%) 9065.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
ZymoTaqTM DNA 
Polymerase Kit 
E2002 
Zymo Research Europe GmbH, Freiburg, 
Germany 
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QIAquick PCR 
Purification Kit  
28106 Qiagen GmbH, Hilden, Germany 
Tris base 4855.3 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Agarose 
N3101-
0500 
STARLAB GmbH, Ahrensbur, Germany 
Ethidium bromide (1%) 2218.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany  
pGEM®-T Vector System 
II 
A3610 Promega GmbH, Mannheim, Germany 
Tryptone/peptone 8952.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Yeast extract 2363.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
NaOH 6771.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Agar 2266.2 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Ampicillin HP62.1 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
IPTG 2316.3 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
X-B-gal 2315.3 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
D-(+)-glucose  16325 Sigma-Aldrich, St. Louis, USA 
Taq DNA polymerase  786-447 G-Biosciences, St Louis, USA 
Anti-CD14 antibody ab27545 Abcam, Cambridge, UK 
Anti-acetyl-histone H3 
antibody 
06-599 Merck Millipore, Darmstadt, Germany  
Anti-acetyl-histone H4 
antibody  
06-866 Merck Millipore, Darmstadt, Germany 
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Anti- NF-κB p65 antibody  ab72555 Abcam, Cambridge, UK 
Anti- NF-κB p105/p50  ab47336 Abcam, Cambridge, UK 
Anti-β-actin (C4) antibody sc-47778 
Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
Goat anti-mouse IgG-HRP  sc-2005 
Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
Clarity™ ECL Western 
Blotting Substrate  
170-5060 
Bio-Rad Laboratories GmbH, München, 
Germany 
TNFα Pig ELISA Kit Ab100756 Abcam, Cambridge, UK 
IL-1β Pig ELISA Kit Ab100754 Abcam, Cambridge, UK 
 
 
 
 
 
 
 
 
 
 
 
 
                               Material and methods                    27 
 
3.1.2 Buffer, media and gels 
1× PBS (without Ca2+ and Mg2+, pH 7.4)   (g/L) 
NaCl  8 
Na2HPO4.2H2O  1.44 
KCl  0.20 
KH2PO4  0.24 
PAMs washing PBS  Percentage (%) 
1× DPBS (without Ca2+ and Mg2+, pH 7.4)    90 
Fungizone® antimycotic  5 
Pen-Strep  5 
1× RBC lysis buffer  (g/L) or (ml/L) 
NH4Cl  8.30 g/L 
KHCO3  1 g/L 
5% EDTA   1.80 ml/L 
ddH2O added to   1 L 
PAMs culture medium  Percentage (%) 
RPMI 1640 medium  87 
FBS  10 
Pen-Strep (100× concentrate)  1 
Fungizone® antimycotic   1 
Gentamicine (10 mg/ml)  1 
Cell count medium  ul 
Cell suspension  10 
4% Trypan blue stain  50 
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PAMs culture medium  40 
Tris-acetate-EDTA (TAE) (10×)  ml/L or g/L 
Acetic acid (100%)  571 ml 
Tris base  242 g 
EDTA  100 ml 
ddH2O  added to 1 L 
Agarose gel  2% 
Agrose  4 g 
TAE (1×)  200 ml 
Ethidium bromide  9 µl 
LB medium with ampicillin   
Tryptone  10 g 
Yeast extract  5 g 
NaCl  5 g 
Adjust pH to 7.0 with NaOH    
Agar  15 g 
Autoclave, cool to 50 °C, adding    
Ampicillin  5 ml 
SOC medium   500 ml 
Tryptone  10 g 
Yeast extract  2.50 g 
1 M NaCl  5 ml 
1 M KCl  1.25 ml 
dd H2O  485 ml 
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Autoclave, cool to room temperature,  
Adjust pH to 7.0 with NaOH 
  
2 M Mg2+ stock (filter-sterilized)  5 ml 
2 M glucose (filter-sterilized)  5 ml 
dd H2O  Adding to 500 ml 
dNTP solution    400 ml 
dATP (100 mM)  10 µl 
dGTP (100 mM)  10 µl 
dTTP (100 mM)  10 µl 
Add ddH2O to  400 ml 
Acrylamide gradients SDS-PAGE  8% 10% 12% 15% 
Acrylamide (30%) 1.33 ml 1.67 ml 2.00 ml 2.50 ml 
Separating gel buffer 1.25 ml 1.25 ml 1.25 ml 1.25 ml 
ddH2O 2.32 ml 2.00 ml 1.67 ml 1.15 ml 
APS (Aliquot in -20 °C)  25 µl 25 µl 25 µl 25 µl 
Temed 5 µl 5 µl 5 µl 5 µl 
Sample gel                 5.6% 
Acrylamide (30%)                      0.725 ml 
Sample gel buffer                      0.500 ml 
ddH2O                      2.825 ml 
APS                      38 µl 
Temed             5 µl 
10× blotting buffer          1 L  
Tris               30.3 g 
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Glyzin              144.0 g 
ddH2O              1 L 
pH 8.3  
1× blotting buffer       1 L  
10× blotting buffer             100 ml 
Methanol             200 ml 
ddH2O             700 ml 
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3.1.3 Equipment and consumables 
Equipment/consumables Manufacturer/Supplier 
Cell strainer (70 μm) BD Biosciences, Heidelberg 
Rotilabo® filter 0.22 μm 
Carl Roth GmbH + Co. KG, 
Karlsruhe 
Centrifuge tubes (15 ml, 50 ml) 
SARSTEDT AG & Co., 
Nümbrecht 
Centrafuge (5810R, 5424, 5416, 5415R) Eppendorf AG, Hamburg 
Haemocytometer 
Paul Marienfeld GmbH & Co. 
KG, Lauda-Königshofen 
Microscope (ECLIPSE TS100)  Nikon GmbH, Düsseldorf 
Digital camera system for microscopy digital 
sight series (DS-Fi1)  
Nikon GmbH, Düsseldorf 
Memmert CO2 incubator 
Fisher Scientific UK Ltd, 
Loughborough 
6 - well cell culture plates STARLAB GmbH, Hamburg 
24 - well cell culture plates STARLAB GmbH, Hamburg 
96 - well cell culture plates STARLAB GmbH, Hamburg 
Serological pipettes (1,2, 5, 10, 25 ml) 
Greiner Bio-One GmbH, 
Frickenhausen 
Aspirating pipette 
Greiner Bio-One GmbH, 
Frickenhausen 
Cell scrapers 
Greiner Bio-One GmbH, 
Frickenhausen 
Plate reader synergy™ 2 
BioTek Instruments GmbH, Bad 
Friedrichshall 
FACSCanto flow cytometer  
BD Biosciences GmbH, 
Heidelberg 
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StepOnePlus™ real time PCR system 
Life Technologies GmbH, 
Darmstadt (Applied 
Biosystems®) 
MicroAmp® fast optical 96-well reaction plate 
with barcode, 0.1 ml 
Life Technologies GmbH, 
Darmstadt (Applied 
Biosystems®) 
CEQ8000 sequencer system (CEQ8000) 
Beckman Coulter, Inc., Fullerton, 
CA 
Water-bath 1083 
GFL Gesellschaft für 
Labortechnik mbH, Burgwedel 
Nanodrop 8000 spectrophotometer 
Thermo Fisher Scientific 
Biosciences GmbH, St. Leon-
Roth 
Universal high speed centrifugation (Z300 K, 
Z300, Z200 M/H, Z233 MK, Z323 K) 
HERMLE Labortechnik 
GmbH,Wehingen 
ELV fully automatic autoclave (3870) 
Tuttnauer Europe B.V., 
Netherlands 
Multi®-ultra tubes 0.65 ml 
Carl Roth GmbH + Co. 
KG,Karlsruhe 
SafeSeal® tubes 1.5 ml 
Carl Roth GmbH + Co. KG, 
Karlsruhe 
SafeSeal® tubes 2.0 ml 
Carl Roth GmbH + Co. 
KG,Karlsruhe 
PCR® strip tubes 
VWR International GmbH, 
Darmstadt (Axygen®) 
Pipette tips (10 µl, 200 µl, 1000 µl) Labomedic GmbH, Bonn 
Pipettes (0.5 - 10, 2 - 20, 20 - 200, 100 - 1000 
μl) 
Eppendorf AG, Hamburg 
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3.1.4 Software programs and statistical packages 
Software Using for Sources  
Primer 3 qRT-PCR primer design http://simgene.com/Primer3 
BLAST Check alignment specificity 
http://blast.ncbi.nlm.nih.gov/Blast.
cgi 
MethPrimer 
Bisulfite PCR primers 
design, CpG islands 
prediction 
http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi 
BiQ Alalyzer Bisulfite sequence analysis  
http://biq-analyzer.bioinf.mpi-
inf.mpg.de/index.php 
FlowLogic® 
software 
Flow cytometry analyses BD Biosciences, Germany 
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3.2 Methods 
3.2.1  Experimental animals 
A total of three 35-days-old female GL piglets (after weaning) were used in this study. 
Animals were fed in the same environmental conditions in the teaching and research 
station of Frankenforst, University of Bonn, Germany. The feeding and husbandry 
practices of the animals followed the husbandry regulations and standard guidelines 
(ZDS, 2003). The experiment was approved by the Veterinary and Food Inspection 
Office, Siegburg, Germany (the number of permission: 39600309-547115). The piglets 
were selected from one litter and all of them were free from all major pig diseases. At 
the age of 28 days, piglets were weaned and placed in collective pens.  
3.2.2  PAMs cells isolation from lungs of the GL piglets 
Animals were humanely euthanized with a dose of ketamine and afterwards T61 
(adjusted to the individual body weight) through the vena cava cranialis. After the 
animals had been euthanized, the chest and abdominal skin was disinfected with 
meliseptol. The thorax was opened gently and the whole lung was removed with trachea 
carefully. Afterwards, the lungs were washed with ice-cold sterile calcium-magnesium-
free phosphate buffered saline (PBS) (1×, pH 7.4), then transported on ice to laboratory. 
At the laboratory, lungs were taken out from the ice box, washed with 1× PBS (4 °C) 
again and put on the aluminium foil on ice. The PAMs from porcine lungs were 
obtained by bronchoalveolar lavage (BAL) using ice-cold PBS medium, as described by 
Islam (Islam et al. 2012), with some modifications. Sterile PBS medium (300 - 400 ml) 
was poured into the lungs with plastic dropper for 6 - 8 times and gently massaged 30 
sec, The lavage fluid was collected in a sterile bottle and filtered by using sterile gauze. 
Afterwards, it was filtered by 70 μm cell strainer. The PAMs were precipitated by 
centrifuge with 1,500 rpm for 10 min at 4 °C. After centrifugation, the supernatant was 
completely and carefully removed. To remove the red blood cells (RBCs), the isolated 
cells were treated with 5 ml 4 °C red blood cell (RBC) lysis buffer solution for 5 min 
incubation at room temperature, aiming to prevent the contamination of red blood cells. 
The reaction of lysis buffer was stopped with 20 ml sterile Dulbecco’s phosphate 
buffered saline (DPBS, 1×, pH 7.4, Life Technologies, Darmstadt, Germany) and a cell 
pellet was produced by centrifugation (1,500 rpm for 10 min, 4 °C). 
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The RBC lysis reaction process was repeated as often as required until all the red blood 
cells were removed completely. Supernatant was removed carefully and cell pellet was 
washed with sterile DPBS (1×, 4 °C, pH 7.4, Life Technologies, Darmstadt, Germ-any), 
then suspended by PAMs culture medium (37 °C) including 87% Roswell Park 
Memorial Institute (RPMI) 1640 medium (GlutaMAX™) (Life Technologies, 
Darmstadt, Germany), 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (Pen-
Strep) (100× concentrate, Life Technologies, Darmstadt, Germany), 1% fungizone® 
antimycotic (Life Technologies, Darmstadt, Germany) and 1% gentamicine (10 mg/ml, 
Life Technologies, Darmstadt, Germany). Cells were counted in a haemocytometer with 
the final cell suspension in 10 times dilution using 4% trypan blue stain and PAMs 
culture medium and the viability of cells also was determined on the basis of trypan 
blue dye exclusion. Then cells were cultured in PAMs culture medium in a 5% CO2 
humidified cell culture incubator at 37 °C.  
3.2.3 PAMs cell morphology detection 
PAMs were seeded in a poly-D-lysine-coated 6 - well cell culture plates (2 × 106 
cells/ml) to observe the cell morphology. The medium was changed every second day. 
Morphology of PAMs on day 3, 5, 7, 12, 18 and 29 was evaluated by Microscope 
(ECLIPSE TS100, Nikon GmbH, Düsseldorf). 
3.2.4 Cell characterization by flow cytometry analyses 
Cell characterization were done by flow cytometry assay using FACSCanto flow 
cytometer (BD Biosciences, Heidelberg, Germany) and FlowLogic® software (BD 
Biosciences, Germany) with one cell marker CD163 (Abdserotec, cat. MCA2311F). 
PAMs were harvested, washed with sterile DPBS and cell numbers were counted by 
hemocytomer. Afterwards, 1 × 106 cells were incubated with 10 μL of conjugated 
antibody CD163 for 30 min at 4 °C. Cells were stained according to the manufacturer. 
Cells were washed two times and re-suspended in 1 ml and 400 µl flow cytometry 
staining buffer, respectively. Assay was performed by FACSCanto flow cytometer and 
the results were analyzed by using FlowLogic® software. 
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3.2.5 Treatment of PAMs with LPS and SFN 
PAMs were seeded in poly-D-lysine-coated 24 - well cell culture plates (5 × 105 
cells/ml) with 1 ml medium for LPS treatment in different time points to isolate total 
RNA. Cells were also seeded in 96 - well (1 × 105 cells/ml) plates with 100 µl medium 
for 48 h to perform cell viability assays. Thereafter, cell culture medium was changed 
every two days. On day 9, cells were treated with 5 µg/ml of LPS (LPS from E.coli 
0111:B4, Invivogen, USA) for 1, 3, 6, 12, 24, 36 and 48 h (Fig. 8AB). Cells without 
LPS treatment served as a vehicle control (Fig. 8AB). 
 
Fig. 8 (A) PAMs with LPS treatment in different time points in 24-well plates  
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Fig. 8 (B) PAMs with LPS treatment in different time points in 96-well plates for cell 
viability test  
(×: means wells were not used) 
S - SFN (Biomol GmbH, Hamburg, Germany) was prepared in dimethyl sulfoxide 
(DMSO) and stored as a stock concentration of 50 mmol/L at -20 °C. PAMs were 
seeded in the poly - D - lysine - coated 6 - well cell culture plates (2 × 106 cells/ml) with 
3 ml medium to isolate total RNA. Cells also were seeded in 96 - well (1 × 105 cells/ml) 
plates with 100 µl medium for 48 h to perform cell viability assays. On day 7, cells 
were treated with 0, 5, 10 µM SFN respectively (the maximum concentration of DMSO 
was 0.05% (v/v) in the medium) for 48 h. Cells treated only with DMSO served as 
control. Cells were treated with 5 µg/ml of LPS for 12 h subsequently. PAMs were also 
treated with SFN (0, 5, 10 µM) on day 7 for 48 h and LPS (0 or 5 µg/ml) on day 9 for 12 
h in six groups (SFN0-LPS0; SFN0-LPS5; SFN5-LPS0; SFN5-LPS5; SFN10-LPS0; 
SFN10-LPS5) in 6-well plates, group SFN0-LPS0 served as a control (Fig. 9AB). 
38                            Material and methods                                    
 
 
Fig. 9 (A) PAMs with SFN and LPS treatment in 6-well plates (3 plates) 
 
 
Fig. 9 (B) PAMs with SFN and LPS treatment in 96-well plate for cell viability test  
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3.2.6 Cell viability assay  
The cell viability of PAMs was measured with water - soluble tetrazolium salt - 1 
(WST-1) Cell Proliferation Assay Kit (Biomol GmbH, Hamburg, Germany). Cells were 
seeded in a 96 - well plates at a density of 1 × 105 cells/well in 100 µl of PAMs culture 
medium (Fig. 8B and 9B). For PAMs with/without LPS treatment, cells were 
challenged with 5 µg/ml LPS for 48, 36, 24, 12, 6, 3, 1 h on day 9 (Fig. 8B). For PAMs 
with/without LPS-SFN treatment, cells were challenged with SFN (0, 5, 10 µM) on day 
7 for 48 h and LPS (0, 5 µg/ml) on day 9 for 12 h (Fig. 9B). At the end of stimulation, 
the old cell supernatant was aspirated and the fresh PAMs culture medium was added. A 
volume of 10 µl of the reconstituted WST-1 solution was added to each well. Cells were 
incubated for two h at 37 °C in the 5% CO2 incubator. Then the supernatant was 
transferred to a new 96 - microplate and the absorbance of each sample was measured at 
a wavelength of 450 nm on the plate reader Synergy™ 2 (BioTek Instruments GmbH, 
Bad Friedrichshall, Germany). 
Quantitative cell viability data was expressed as means ± SD, n = 3. The statistical 
analysis of data was investigated with SAS (version 9.3) using the general linear model 
containing the LPS and SFN treatments as fixed effects. The *P < 0.05, **P < 0.01 and 
***P < 0.001 were set as statistically significant. 
3.2.7 RNA extraction, cDNA synthesis and real-time PCR 
Total cellular RNA was isolated from PAMs using the AllPrep® DNA/RNA/Protein 
Mini Kit (Qiagen, Germany) according to the manufacturer’s instruction. Cells were 
disrupted by buffer RLT and the cell lysate was homogenized by a vortex mixer. RNA 
was bound with RNeasy spin column and washed with 700 μL buffer RW1 and 500 μL 
buffer RPE (2 times). Then the RNA was eluted with 30 µl ribonuclease (RNase) - free 
water and the concentration was measured by Nanodrop 8000 spectrophotometer.  
200 ng of total RNA were reverse transcribed into first strand cDNA using the First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific Biosciences GmbH, St. Leon-Rot 
, Germany). The reaction system, which included 0.5 µl oligo (dT)18 primer (100 µM, 
0.5 µg/µl), 0.5 µl random hexamer primer (100 µM, 0.2 µg/µl), nuclease-free water and 
total RNA (200 ng) up to 11 µl, was mixed gently, centrifuged briefly and incubated at 
65 °C for 5 min and then quick chilled on ice. Afterwards, 4 µl 5 × reaction buffer (250 
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mM Tris-HCl (pH 8.3), 250 mM KCl, 20 mM MgCl2, 50 mM DTT), 1 µl Ribolock 
RNase inhibitor (20 U/µl), 2 µl dNTP Mix (10 mM) and 2 µl M-MuLV reverse 
transcriptase (20 U/µl) were added to the reaction tube with a total volume of 20 µl. 
Reaction tube was mixed gently and centrifuged for 30 sec and incubated at 25 °C for 5 
min, 37 °C for 60 min and 70 °C for 5 min. cDNA concentrations were also measured 
by Nanodrop 8000 spectrophotometer.  
The qRT-PCR was performed by using iTaqTM Universal SYBR® Green Supermix 
(Bio-Rad Laboratories GmbH, Germany). PCR primers (Table 2) were designed by 
using Primer 3 on line tool (http://simgene.com/Primer3) or chosen from the literature 
and additionally proofed with BLAST (basic local alignment search tool) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure specificity. The pig glyceraldehyde - 3 
- phosphate dehydrogenase (GAPDH) gene was selected as the house keeping gene. The 
total volume of 20 µl for each qRT-PCR reaction consisted of 100 ng cDNA, forward 
(F) and reverse (R) primers, RNase - and deoxyribonuclease (DNase) - free water and  
10 μL of iTaq™ Universal SYBR® Green Supermix (2×). qRT-PCR amplification was 
conducted with 95 °C for 3 min; 95 °C for 15 sec, 60 °C for 45 sec (40 cycles); 95 °C 
for 15 sec, 62 °C for 1 min, 95 °C for 15 sec (Melt-Curve) by  using StepOnePlus™ 
Real time PCR System (Applied Biosystems®).  
Gene-specific expression was measured as relative to the geometric mean of the 
expression of the housekeeping gene GAPDH. The delta Ct (∆Ct) values were 
calculated as the difference between target gene and reference gene. 
∆Ct = Cttarget - Cthousekeeping gene 
The relative gene expression was calculated as 2(-∆Ct) and the fold change in expression 
between the treated and untreated PAMs was calculated as 2(-∆Cttreated
)/ 2(-∆Ctcontrol
) 
(Schmittgen and Livak KJ, 2008) (control: untreated group SFN0-LPS0). Relative gene 
expression levels were checked for outliers. Outliers were identified when these values 
deviating more than three standard deviations from the raw mean. These extreme values 
were eliminated from future analysis. Data was analyzed by SAS (version 9.3) with 
liner mixed model: 
 Y = LPS + SFN + LPS * SFN + animal + e  
Y:  fold change; animal: random effect of the animal; e: residuals 
Group means were expressed as least square means (± standard error (SE)). The values 
were tested by a Dunnett - Hsu test in order to identify significant differences compared 
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to the control group (SFN0-LPS0). In addition, a Tukey - Kramer test (pair wise 
comparisons) was performed to compare other classes with each other. The (* and #) P 
< 0.05, (** and ##) P <0.01, (*** and ###) P < 0.001 were set as statistically 
significant. 
Table 2 Primers and their sequences for RT-PCR 
F R 
CD14 5'-TGG ACC TCA GTC ACA ACT CG-3' 5'-CCT TTA GGC ACT TGC TCC AG-3' 
TRAM 5'-GTC TCC TGT ATG GCG ATG GT-3' 5'-TCT GTT GCA GGG AGG GTA AC-3' 
TRIF 5'-CAC CTC CTT GTG GAG GAG AA -3' 5'-GAC GTC CTC CAT GTC CCT AA -3' 
TRAF6 5'-CTG GAC GCC CTA AGA CAG AG-3' 5'-AAC CCT CCC TCC GAA GAC TA-3' 
RIPK1 5'-AAA CTG ACG AAG GAG GAG CA -3' 5'-CAG ATG GCA TTT TCG TAG GG-3' 
TRAF3 5'-CTC CTC CAG CCC AAA ATG TA-3' 5'-TTC TTC AAA TGC ACC AGC AG-3' 
NF-κB 5'-TGG GAA AGT CAC AGA AAC CA-3' 5'-CCA GCA GCA TCT TCA CAT CT-3' 
TNFa 5'-TCC TCA CTC ACA CCA TCA GC-3' 5'-CCA AAA TAG ACC TGC CCA GA-3' 
IL-1β 5'-GTA CAT GGT TGC TGC CTG AA-3' 5'-CTA GTG TGC CAT GGT TTC CA-3' 
IL-6 5'-GGC AGA AAA CAA CCT GAA CC -3' 5'-GTG GTG GCT TTG TCT GGA TT-3' 
IL-12-p40 5'-ATG CAC CTT CAG CAG CTG GTT G-3' 5'-CTA ATT GCA GGA CAC AGA TGC-3' 
IRF7 5'-ACA CTC TAC CCC CGT GTC TG-3' 5'-AGA CCC GTA CAG GAG CAC AC-3' 
IRF3 5'-TTC CTG AGC CAG ACA CCT CT-3' 5'-ACT CCC ACT CGT CGT CAT TC-3' 
IFN-α 5'-TTC CAG CTC TTC AGC ACA GA-3' 5'-ATG ACA CAG GCT TCC AGG TC-3' 
IFN-β 5'-ACC TGG AGA CAA TCC TGG AG-3' 5'-AGG ATT TCC ACT TGG ACG AC-3' 
GAPDH 5'-CAA GCA GTT GGT GGT ACA GG-3' 5'-GCT GGT GCT GAG TAT GTC GT-3' 
DNMT1 5'-GCG GGA CCT ACC AAA CAT-3' 5'-TTC CAC GCA GGA GCA GAC-3' 
DNMT3a 5'-CTG AGA AGC CCA AGG TCA AG-3' 5'-CAG CAG ATG GTG CAG TAG GA-3' 
F = Forward, R = Reverse 
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3.2.8 Protein extraction and Western blot analysis 
Total cellular protein purification was performed by using the AllPrep® 
DNA/RNA/Protein Mini Kit (Qiagen, Germany) according to the manufacturer’s 
instruction. One volume (700 µl) of buffer APP was added to the flow-through from 
RNA-extraction step. Tubes were mixed vigorously and incubated at room temperature 
for 10 min to precipitate protein and centrifuged at 12,000 rpm for 10 min. The 
supernatant was decanted carefully. A volume of 500 μL of 70% ethanol was added to 
the protein pellet, centrifuged at 12,000 rpm for 1 min. The supernatant was removed 
and the protein pellet was dried for 5-10 min at room temperature. Afterwards, 50 µl 
buffer ALO were added and mixed vigorously to dissolve the protein pellet, incubated 
for 5 min at 95 °C to completely dissolve and denature the protein. Samples were 
cooled to room temperature, then centrifuged for 1 min at 12,000 rpm to pellet any 
residual insoluble material. The supernatant of protein was transferred to a new 1.5 ml 
tube and saved in -80 °C for Western blotting. 
Equal amounts of protein extracts from the PAMs were loaded and separated by using 
8-12% acrylamide gradients sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis (SDS-PAGE). After running the gel, proteins were transferred from gel 
to a membrane. The membrane was incubated with primary antibodies (anti-CD14 
antibody (1:400, Abcam), anti-acetyl-Histone H3 polyclonal antibody (1:1000, 
Millipore), anti-acetyl-Histone H4 polyclonal antibody (1:2000, Millipore), anti- NF-κB 
p105 / p50 (phospho S932) antibody (1:500, Abcam) and anti-β-actin (C4) (1:500, 
Santa Cruz Biotechnology, Inc.)). Signals were detected by a secondary antibody (goat 
anti-mouse immunoglobulin G - horseradish peroxidase (IgG-HRP) (1:8000, Santa Cruz 
Biotechnology, Inc.)). The specific signals of immunoreactive bands were detected by 
chemiluminescence using Clarity™ ECL Western Blotting Substrate (1:1000, Bio-Rad 
Laboratories GmbH). Images were acquired by Quantity One 1-D analysis software 
(Bio-Rad).  
3.2.9 ELISA analysis of cytokines 
PAMs cells culture supernatants were collected after PAMs stimulation with or without 
SFN for 48 h and LPS for 12 h (from the arrangement treatment groups Fig. 9A) to 
measure cytokines by Enzyme-linked immunosorbent assay (ELISA). IL-1β and TNF-α 
cytokines levels were measured by using porcine specific ELISA kits (Abcam, 
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Cambridge, UK) with the sensitivity of minimum detectable dose as 6 pg/ml (less than) 
and 20 pg/ml (less than), respectively. Assays were conducted in 96-well microplates 
according to the manufacturer’s instruction and the absorbance of 450 nm was 
measured on the plate reader Synergy™ 2 (BioTek Instruments GmbH, Bad 
Friedrichshall, Germany).  
Data was expressed as mean ± SD, n=3. The statistical differences between protein level 
values were analyzed by SAS (version 9.3) using the general linear model. The *P < 
0.05, **P <0.01 and ***P < 0.001 were set as statistically significant. 
3.2.10  CD14 CpG islands prediction 
The CD14 promoter region and the complete coding sequence (CDS) (GenBank 
DQ079063.1, 1762 bp) (Sanz et al. 2007) were submitted to the online program: 
Methprimer (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) to identify 
the CGIs. 
3.2.11  Genomic DNA extraction  
PAMs were cultured in 6 - well plates at a density of 2 × 106 cells/well and were treated 
with SFN on day 7 for 48 h followed by 12 h stimulation of LPS on day 9 (Fig. 9A). 
gDNA was extracted by using buffer EB by AllPrep® DNA/RNA/Protein Mini Kit 
(Qiagen, Germany). Cells were disrupted by buffer RLT and the cell lysate was 
homogenized by a vortex mixer. The gDNA was bound with an AllPrep DNA spin 
column placed in a 2 ml collection tube from the homogenized lysate. The gDNA was 
washed by 500 μL buffer AW1 and 500 μL buffer AW2, afterwards, eluted by buffer 
EB (preheated to 70 °C) with 2 min incubation at room temperature (15 - 25 °C) and 1 
min centrifugation at 10,000 rpm. The concentration of gDNA was measured by 
Nanodrop 8000 spectrophotometer. 
3.2.12  Bisulfite conversion of gDNA  
To assess the methylation status of CD14 gene promoter and complete CDS, sodium 
bisulfite methylation sequencing was performed. 300 ng purified gDNA were used for 
bisulfite conversion followed the protocol of EZ DNA Methylation-DirectTM Kit (Zymo 
Reserch, Freiburg, Germany). Cytosine-thymidine (CT) conversion reagent was 
prepared by adding 790 μL of M-solubilization buffer and 300 μL of M-dilution buffer 
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by following 10 min frequent vortex at room temperature, then adding 160 μL of M-
reaction buffer and mixing an additional 1 min. M-wash buffer was prepared by adding 
24 ml of 100% ethanol. A total amount of 300 ng gDNA and ddH2O with a volume of 
20 µl were added to 130 µl of CT conversion reagent solution in a PCR tube, mixed and 
then centrifuged briefly. The PCR tubes were placed in a thermal cycler and incubated 
by 8 min at 98 °C, 3.5 hours at 64 °C and 4 °C storage for up to 20 h. A volume of 600 
µl of M-binding buffer was added into a Zymo-Spin™ IC column which was placed 
into a provided collection tube. The sample of gDNA with CT conversion reagent 
solution was loaded into the Zymo-Spin™ IC column containing the M - binding buffer 
after finishing the thermal cycler program, mixed by inverting the column several times, 
then centrifuged at full speed (> 10,000 × g) for 30 sec. Afterwards, 100 μl of M-wash 
buffer were added to the column and centrifuged at full speed for 30 sec. Then 200 μl of 
M-desulphonation buffer were added to the column with 15 - 20 min incubation at room 
temperature (20 - 30 °C) and 30 sec centrifugation at full speed. A volume of 200 μl of 
M-wash buffer was added to the column and centrifuged at full speed for 30 sec, this 
step was repeated one time. The bisulfite conversed gDNA was eluted by 10 μl of M-
elution buffer with 30 sec centrifugation at full speed and measured by Nanodrop 8000 
spectrophotometer and stored at - 20 °C. 
3.2.13  Bisulfite PCR amplification and PCR purification  
Bisulfite PCR was performed by ZymoTaqTM DNA Polymerase Kit (Zymo research, 
Germany) using touchdown PCR. Bisulfite PCR primers (9 primers: CD1401 to 
CD1409, Table 3) of CD14 promoter region and complete CDS (GenBank 
DQ079063.1, 1762 bp) were designed by using MethPrimer 
(http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) online software. In the 
PCR reaction, 12.5 µl 2× reaction buffer, 0.4 µl dNTP Mix (25 mM each dNTP), 0.5 µl 
Forward Primer (10 µM), 0.5 µl Reverse Primer (10 µM), 1 µl bisulfite gDNA, 0.2 µl 
ZymoTaqTM DNA polymerase (5 U/µl) and DNase/RNase - Free H2O were added for a 
total volume of 25 µl. The reaction program of bisulfite touchdown PCR is displayed in 
table 4. 
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Table 3 Primers for bisulfite PCR 
Primer              F (5′-3′) R (5′-3′) 
Product 
size (bp) 
CD1401 AGGGAAAAGTTAAGGAAATTTTTTG 
CAAAACCTCTAAAATCCTTAACACTA
AAC 
169  
CD1402 GGATTTTAGAGGTTTTGTAAGATTTTTY ACTCCCTAACTTCCAAACTCCAC 248  
CD1403 GGAGTTTGGAAGTTAGGGAGTGT CAACAAAAACAACAACAACAACAA 219  
CD1404 TTGTTGTTGTTGTTGTTTTTGTTG TTTAAAAAAAACTCTTCCAAACTCC 194  
CD1405 GTTTGGAAGAGTTTTTTTTAAAGAG ACAAAACCAAAACCAAAATCTAAAC 135  
CD1406 GGTTTTTGTTTAGATTTTGGTTTTG TTAACTAAAACCACTACTACAATTC 212  
CD1407 TTTTAGTTAAGTTTTAAGGTATTGAAAGTG AACAAAAAACTACAATCAACCC 151  
CD1408 GGGTTGATTGTAGTTTTTTGTT ACAATCCTTTAAACACTTACTCCAACT 253  
CD1409 TGATTTTGGAAGGGAATTTTTATAT ATTCCCCTTCCTTAAACCTTAAAC 176  
Note: Y-CT 
Table 4 Programs of touchdown PCR for bisulfite primers 
Primer Program  
CD1401  
CD1403 
95 °C for 10 min; 95 °C for 30 sec, 0.5 °C↓/58 °C for 1min (20 cycles); 95 °C for 45 
sec, 48 °C for 1min, 72 °C for 1 min 30 sec (40 cycles); 72 °C for 10 min; 4 °C for ∞ 
 
CD1402 
95 °C for 10 min; 95 °C for 30 sec, 0.5 °C↓/59°C for 1min (20 cycles); 95°C for 45 sec, 
49 °C for 1 min, 72 °C for 1 min 30 sec (40 cycles); 72 °C for 10 min; 4 °C for ∞ 
 
CD1404 
CD1405 
CD1406 
CD1407 
95 °C for 10 min; 95 °C for 30 sec, 0.5 °C↓/55 °C for 1min (20 cycles); 95 °C for 45 
sec, 45 °C for 1 min, 72 °C for 1 min 30 sec (40 cycles); 72 °C for 10 min; 4 °C for ∞, 
 
CD1408 
CD1409 
95 °C for 10 min; 95 °C for 30 sec, 0.5 °C↓/56 °C for 1 min (20 cycles); 95 °C for 45 
sec, 46 °C for 1 min, 72 °C for 1 min 30 sec (40 cycles); 72 °C for 10 min; 4 °C for ∞ 
 
 
The bisulfite touchdown PCR production was purified by using QIAquick PCR 
Purification Kit which was used for purification of 100 bp to 10 kb PCR products. Five 
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volumes of buffer PB were added into 1 volume of bisulfite touchdown PCR samples 
and mixed by pipette. The QIAquick spin columns were placed in provided 2 ml 
collection tubes. The PCR sample-PB solution was loaded into the columns, then 
columns were centrifuged at 12,000 rpm for 1 min. A volume of 750 µl buffer PE was 
added to the QIAquick spin columns, centrifuged at 12,000 rpm for 1 min. The flow-
through was discarded and the column was centrifuged at 12,000 rpm for an additional 
1 min. The column was placed in a new 1.5 ml micro-centrifuge tube. A volume of 30 
µl buffer EB (10mM Tris-HCl, pH 8.5) was added to the center of the QIAquick 
membrane. The column was stand for 1 min and centrifuged for 1 min at 12,000 rpm. 
The purified PCR product (5 µl) was loaded to 2% agarose gel. To check the PCR 
products, the gel was run following by a step at 120 V for 30 min. The concentration of 
purified PCR product was measured by Nanodrop 8000 spectrophotometer.  
3.2.14  Cloning  
The purified bisulfite touchdown PCR products were cloned by using pGEM®-T Easy 
Vector Systems (Promega GmbH, Germany). The ligation reaction system was set as 
described below (Table 5). Reaction was mixed by pipette and incubated overnight at 4 
°C.  
Table 5 Ligation reaction system 
Reaction component Standard 
reaction 
Positive 
control 
Background 
control 
2× Rapid ligation buffer, T4 DNA ligase 5 μl 5 μl 5 μl 
pGEM®-T easy vector (50 ng) 1 μl 1 μl 1 μl 
Purified PCR product 3 μl 0 μl 0 μl 
Control insert DNA 0 μl 2 μl 0 μl 
T4 DNA ligase 1 μl  1 μl 1 μl 
Nuclease-free water 0 µl 1 μl 3 μl 
Total reaction volume 10 µl 10 µl 10 µl 
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The transformation was performed by using JM109 High Efficiency Competent Cells. 
LB/ampicillin/IPTG/X-Gal plates were prepared. The JM109 High Efficiency 
Competent Cells were removed from -80 °C freezer and placed in an ice bath until just 
thawed (about 5 min) and mixed by gently flicking the tubes. The ligation reaction tubes 
were centrifuged briefly and 5 µl of ligation reaction were put into sterile 1.5 ml tubes 
on ice, then 100 µl of competent cells were added. The tubes were flicked gently to mix 
and placed on ice for 20 min. Then cells were heat-shocked in a water bath at exactly 42 
°C without shake for 45 - 60 sec and returned immediately to ice for 2 min. A volume of 
950 μL SOC medium was added to the ligation reaction transformations and incubated 
for 1.5 hours at 37 °C with shaking (150 rpm). Cells were centrifuged for 3 min at 1,000 
rmp and re-suspend in 200 µl SOC medium. A volume of 100 μL of each 
transformation cell suspension was poured onto duplicate LB/ampicillin/IPTG/X-Gal 
plates. For the uncut DNA control, a 1:10 dilution with SOC was recommended. The 
plates was incubated overnight (18 h) at 37 °C. White clones (positive clones) were 
selected and picked up for cloning PCR. The blue clones were also picked up for 
cloning PCR as a negative control. 
3.2.15  Cloning PCR 
With the picked clones, a PCR was performed. Cloned DNAs were heated by thermal 
cycler at 95 °C for 15 min. Cloning PCR was performed by Taq DNA polymerase with 
messier 13 (M13) primers (F 5′-TTG TAA AAG GAG GGC CAG T-3′, R 5′-CAG 
GAA ACA GCT ATG ACC, Tm-56 °C). The PCR reaction system was set as described 
below (Table 6) and PCR program was performed with 95 °C for 5 min; 95 °C for 30 
sec, 56 °C for 1 min, 72 °C for 1 min, 40 cycles; 72 °C for 10 min; 4 °C for ret. To 
check the PCR product, 5 µl of each product were loaded to 2% agarose gel. The gel 
was run following a step at 120 V for 30 min. 
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Table 6 The reaction system of M13 cloning PCR 
Reaction component Volume (µl) 
dd H2O   5.8 
10× PCR buffer (Mg2+ plus)   2.0 
dNTPs (10 mM each)   1.0 
Primer (10 µM) F   0.5 
Primer (10 µM) R   0.5 
Cloning DNA   10.0 
Taq DNA polymerase (5 U/μl)   0.2 
Total reaction volume   20.0 
* F-Forward primer, R-reverse primer 
3.2.16  Bisulfite sequencing and DNA methylation analysis 
A minimum of 8 different positive clones (white clones) for each subject were randomly 
selected for sequencing with M13 primer (forward primer) performed by the CEQ8000 
sequencer system (Beckman Coulter, Inc., CA). Bisulfite sequencing data were 
performed with default parameters using BiQ Analyzer on line tool (http://biq-
analyzer.bioinf.mpi-inf.mpg.de/index.php). Sequences with a conversion rate below 
90% were excluded from analysis. 
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4 Results 
4.1 PAMs cell phenotypes  
4.1.1 PAMs cell morphology 
PAMs cell morphology and cell growth state in different time points (day 3, 5, 7, 12, 18 
and 29) were recorded in this study. The PAMs grew as time increased (Fig. 10). Cell 
morphology is mainly characterized by two structures including round shape and 
dumbbell shape (Fig. 10C). Cell feelers grew around cell membrane on day 5 (Fig. 
10B). Cells were confluent on day 12 (Fig. 10D). Most of cells died as cytoplasmic lysis 
on day 29 (Fig. 10F). From these results, we suggested day 9 was chosen for LPS 
treatment and day 7 was chosen for SFN pre-treatment. 
 
Fig. 10 Morphology of PAMs on different days of culture (ABCDF-20×, E-10× under 
microscope). A-day 3, B-day 5, C-day 7, D-day 12, E-day 18, F-day 29.   
4.1.2 Cell characterization by flow cytometry analyses 
Cells were analyzed by flow cytometry, results are shown in Fig. 11. 35% of cells were 
stained with marker CD163. 
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Fig. 11 Flow cytometry results of PAMs with cell marker CD163. The y-axis represents 
the cell population, the x-axis represents the fluorescence. The upper row is the result of 
cells without marker (control) and the lower row is the result of cells with marker 
CD163. Figures with red color mean the rates of cell population. 
4.1.3 LPS affects PAMs cell viability in a time dependent manner 
PAM cells viability was measured by WST-1 Cell Proliferation Assay Kit (Biomol 
GmbH, Hamburg, Germany). LPS at a dose of 5 µg/ml was used to induce 
inflammatory conditions in cultured PAMs. To determine the effective but nontoxic 
time point of LPS treatment on PAMs, we first performed cell viability assay to 
evaluate the cell number and activity. The results show that there was no difference 
between LPS treated cells and control, also between the untreated cells and control at all 
time points (Fig. 12A). When treated and untreated groups were compared, LPS had no 
noticeable effect on the cell viability after 1, 12 and 48 h (1 h, 12 h and 48 h of LPS post 
stimulation, ps) (Fig. 12A). The highest cell viability of both treated and untreated 
PAMs in these three groups was observed at 12 h LPS ps. Therefore, the time point of 
12 h ps was selected for the further study. 
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4.1.4 SFN affects PAMs cell viability in a dose dependent manner 
For the further study, the LPS treatment at time point of 12 h was used as the positive 
control (SFN0-LPS5) and SFN was pre-added in different doses of 0, 5 and 10 µM at 
day 7 for determining the effective dose of SFN on PAMs cell viability. Cell viability of 
SFN5-LPS0 and SFN5-LPS5 had no differences compared to the control group (SFN0-
LPS0) (Fig. 12B). There were significant differences between SFN10-LPS0 and SFN0-
LPS0 (control), as well as between SFN10-LPS5 and SFN0-LPS0 (control) (Fig. 12B). 
SFN pre-treatment significantly increased the cell viability in LPS treated PAMs 
(SFN5-LPS5 and SFN10-LPS5) compared to the positive control (Fig. 12B).  
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Fig. 12 Results of the PAMs cell viability assay. A) The relative cell viability of PAMs 
without and with 5 µg/ml LPS treatment (1, 3, 6, 12, 24, 36, 48 h). B) The relative cell 
viability of PAMs without and with SFN (5, 10 µM) and LPS (5 µg/ml) treatment. All 
of the data were expressed as mean ± SD, n = 3. *, ** and *** indicate significant 
differences at p < 0.05, p < 0.01 and p < 0.001, respectively.  
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4.2 CD14 mRNA expression was induced by LPS in time dependent manner 
To investigate the potential effects of LPS on CD14 expression in PAMs, quantitative 
real-time PCR (qPCR) was performed. The result showed that LPS significantly 
induced CD14 gene expression at time points 1, 6, 12 and 24 h (Fig. 13) while the 
highest expression was displayed at time point 12 h (Fig. 13). At 12 h, gene expression 
of CD14 in LPS treated PAMs was significantly higher than in LPS untreated group 
(LPS0-12 h) and control (LPS0-0 h) (Fig. 13). Theses results indicated that LPS acts on the 
CD14 expression at time points 1, 6, 12 and 24 h, but the greatest effect was at 12 h 
(Fig. 13). The results indicated that LPS induced CD14 expression in a time dependent 
manner (Fig. 13).  
4.3 TRIF downstream genes were induced by LPS 
CD14 directly binds with LPS and activates the MyD88-dependent pathway (Akira and 
Takeda 2004), it may also be involved in TRIF pathway by binding with LPS. Thereby, 
we further analyzed the mRNA expression of CD14 downstream TRIF pathway genes 
including TRAM, TRIF, the TRIF-TRAF6 sub-pathway genes (TRAF6, RIPK1, NF-
κB) and the TRIF-TRAF3 sub-pathway genes (TRAF3, IRF7, IRF3) in 5 µg/ml LPS 
treated PAMs. LPS significantly increased gene expression of CD14, TRIF, TRAF6, 
NF-κB, TRAF3 and IRF7 (Fig. 14 ABC). 
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Fig. 13 Effect of LPS on CD14 mRNA expression in PAMs. Relative CD14 mRNA 
expression in PAMs with or without 5 µg/ml LPS treatment in 7 time points (1, 3, 6, 12, 
24, 36, 48 h) were assayed. mRNA expression without LPS treatment on 0 h was set as 
control. Comparison between treated and untreated cells at one time point is indicated 
as ‘*’. Comparison between treated group and control (0 h) is indicated as ‘#’. All of the 
data are expressed as mean ± SD, n = 3. * (#), ** (##) and *** (###) indicate significant 
differences at p < 0.05, p < 0.01 and p < 0.001, respectively. 
4.4 mRNA expression of CD14 and downstream LPS-induced TRIF pathway genes 
were suppressed by SFN in a dose dependent pattern 
As a HDAC inhibitor, SFN also has anti-inflammatory effects (Ko et al. 2013). To 
explore the effect of SFN on LPS induced inflammation, we examined the relative 
mRNA of CD14 and downstream genes expression in TRIF pathway as illustrated in 
Fig. 14. The results clearly demonstrated that SFN pre-treatment significantly inhibited 
CD14 gene expression (Fig. 14A). We set the SFN0-LPS5 treated cells as the positive 
control. Compared with the positive control, CD14 expression was decreased 
significantly (p < 0.05) in SFN5-LPS5 group.   
SFN suppressed LPS-induced TRAM (p < 0.05) and TRIF (p < 0.001) mRNA expression 
comparing with positive control at the dose of 5 µM (Fig. 14 A). In the TRIF-TRAF6 
pathway, the mRNA expression of TRAF6 and NF-κB genes were decreased in the 
SFN5-LPS5 group compared with the positive control, while the expression of LPS-
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induced RIPK1 gene was inhibited (p < 0.05) by SFN at the doses of 5 µM (Fig. 14 B). 
In TRIF-TRAF3 pathway, SFN suppressed (p < 0.01) LPS-induced TRAF3 expression at 
the dose of 5 µM (Fig. 14 C). These results suggest that the inhibitory effects of SFN on 
LPS-induced TRAM, TRIF, RIPK1 and TRAF3 at the dose of 5 µM might be mediated 
through decreased CD14 mRNA expression. The other genes including TRAF6, NF-κB 
and IRF7 showed the same trend, only IRF3 represented on a contrary trend. Results of 
additional group comparisons can be found in appendix file 1 and 2 (Fig. 21 and Fig. 
22). 
 
Fig. 14 SFN inhibited CD14 mRNA expression and effected on TRIF pathway gene 
expression in PAMs. A) CD14 and downstream genes TRAM and TRIF mRNA 
expression in SFN-LPS stimulated PAMs. B) TRIF-TRAF6 pathway genes mRNA 
expression in SFN-LPS treated PAMs. C) TRIF-TRAF3 pathway genes mRNA 
expression in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) for 24 h 
treatment and LPS (5 µg/ml) for 12 h treatment were used in this assay. mRNA 
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expression in PAMs without SFN and without LPS treatment (SFN0-LPS0) was set as 
control. mRNA expression in PAMs without SFN treatment but with LPS treatment 
(SFN0-LPS5) was set as the positive control. Comparison between treated group and 
control is indicated as ‘*’. Comparison between SFN treated group and the positive 
control is indicated as ‘#’. All of the data were expressed as mean ± SEM, n = 3. *, ** 
and *** indicate significant differences at p < 0.05, p < 0.01 and p < 0.001, 
respectively. 
4.5 Gene expression of LPS-induced cytokines in CD14-TRIF pathway were 
inhibited by SFN in dose dependent manner in PAMs 
Cytokines such as TNFα, IL-1β, IL-6, IL-12p40, IFNα and IFNβ were produced in the 
CD14-TRIF pathway where the first four cytokines are from the TRIF-TRAF6 sub 
pathway and the last two cytokines are from the TRIF-TRAF3 sub pathway. Thus we 
measured the mRNA expression of theses cytokines in the same six groups of cells with 
SFN-LPS treatment. As shown in Fig. 15A, compared with the positive control (SFN0-
LPS5), the gene expression of TNFα was significantly decreased in SFN5-LPS5 (p < 
0.05) group. For IL-1β, the gene expression was suppressed by SFN at both 5 µM (p < 
0.001) and 10 µM (p < 0.001) as compared with the positive control (Fig. 15A). The 
gene expression of IL-6 was suppressed by SFN at 10 µM (p < 0.05) compared with the 
positive control (Fig. 15B). Gene expression of cytokines released from TRIF-TRAF3 
pathway including IFN-α and IFN-β are shown in Fig. 15 C. SFN inhibited LPS-
induced IFN- β expression at the dose of 5 µM (p < 0.001). Results of additional group 
comparisons can be found in appendix file 3 and 4 (Fig. 23 and Fig. 24). 
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Fig. 15 SFN altered mRNA expression of cytokines in TRIF pathway in PAMs. A and 
B) Relative gene expression of TRIF-TRAF6 pathway released cytokines in SFN-LPS 
treated PAMs. C) Relative gene expression of TRIF-TRAF3 pathway released cytokines 
in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) for 24 h treatment 
and LPS (5 µg/ml) for 12 h treatment were used in this assay. Relative mRNA 
expression in PAMs without SFN and without LPS treatment (SFN0-LPS0) was set as 
control. Relative mRNA expression in PAMs without SFN but with LPS treatment 
(SFN0-LPS5) was set as the positive control. Comparison between treated group and 
control is indicated as ‘*’. Comparison between SFN treated group and the positive 
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control is indicated as ‘#’. All of the data were expressed as means ± SEM, n = 3. *, ** 
and *** indicate significant differences at p < 0.05, p < 0.01 and p < 0.001, 
respectively. 
4.6 Protein levels of pro-inflammatory cytokines TNFα and IL-1β were suppressed by 
SFN  
Productions of cytokines including TNFα and IL-1β were measured by ELISA (Fig. 
16). To our surprise, we found that both LPS-induced TNF-α and IL-1β production was 
suppressed by 5 µM and 10 µM SFN. The results clearly show that LPS induced TNF-α 
and IL-1β production. The level of TNF-α in SFN0-LPS5 cells was significantly (p < 
0.001) increased compared with the control group and the level of IL-1β in the same 
group was also significantly (p < 0.05) higher than the control group. Treatment with 
SFN reduced the production of TNF-α with significant effects for SFN5-LPS0 (p < 
0.001), SFN5-LPS (p < 0.001), SFN10-LPS0 (p < 0.01) and SFN10-LPS5 (p < 0.01) as 
compared with the positive control. SFN also significantly repressed IL-1β production 
in SFN5-LPS0 (p < 0.001), SFN5-LPS (p < 0.001) and SFN10-LPS0 (p < 0.01) groups 
as compared to the positive control.  
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Fig. 16 Levels of pro-inflammatory cytokines TNFα and IL-1β were suppressed by SFN 
treatment. A) Levels of TNFα were suppressed by SFN, B) Levels of IL-1β were 
suppressed by SFN. TNF-α and IL-1β were measured by ELISA. PAMs with or without 
SFN (5, 10 µM) for 24 h treatment and LPS (5 µg/ml) for 12 h treatment were used in 
this assay. The cytokine level in PAMs without SFN and without LPS treatment (SFN0-
LPS0) was set as control. Cytokine level in PAMs without SFN treatment but with LPS 
treatment (SFN0-LPS5) was set as the positive control. Comparison between treated 
group and control is indicated as ‘*’. Comparison between SFN treated group and the 
positive control is indicated as ‘#’. All of the data were expressed as means ± SD, n = 3. 
* (#), ** (##) and *** (###) indicate significant differences at p < 0.05, p < 0.01 and p < 
0.001, respectively. 
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4.7 NF-κB protein expression was inhibited by SFN 
To next examine whether SFN regulates the activation of NF-κB in LPS-treated PAMs, 
we analyzed the NF-κBp50/105 protein expression. Our results show that NF-κBp50 
and p105 were upregulated in LPS treated PAMs (Fig. 17). But SFN pretreatment 
caused a dose-dependent decrease of LPS-induced P50/105 translation (Fig. 17).  
 
Fig. 17 NF-κB protein expression was inhibited by SFN 
4.8 Gene expression of the epigenetic enzymes DNMT1 and DNMT3a were altered 
by SFN 
To further investigate the epigenetic modulations that occurred in CD14 caused by SFN, 
we assessed the expression of DNMT1 and DNMT3a in SFN-LPS treated PAMs (Fig. 
18). To our surprise, we discovered that SFN considerably inhibit DNMT1 and 
DNMT3a expression in a dose-dependent manner. Compared with the positive control 
(SFN0-LPS5), the DNMT1 expression was decreased in SFN5-LPS5 group. The LPS-
induced DNMT3a expression was suppressed (p < 0.05) by 5 µM SFN. Results of 
additional group comparisons can be found in appendix file 5 and 6 (Fig. 25 and Fig. 
26). 
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Fig. 18 SFN altered DNMT1 and DNMT3a gene expression. Relative DNMT1 and 
DNMT3a gene expression were measured in SFN-LPS treated PAMs. PAMs with or 
without SFN (5, 10 µM) for 24 h treatment and LPS (5 µg/ml) for 12 h treatment were 
used in this assay. Relative mRNA expression in PAMs without SFN and without LPS 
treatment (SFN0-LPS0) was set as control. Relative mRNA expression in PAMs 
without SFN treatment but with LPS treatment (SFN0-LPS5) was set as the positive 
control. Data are expressed as means ± SEM, n = 3, # indicate significant differences at 
p < 0.05. 
4.9 CpG islands prediction of CD14 promotor and CDS 
To further understand the epigenetic regulation of CD14, we analyzed the CpG islands 
and CpG sites distribution in CD14 promotor region including the 5’-UTR (1- 492 bp) 
and CD14 gene body region (CDS) (from 493 bp to1694 bp) (GenBank DQ079063.1, 
1762 bp of whole sequence) by using MethPrimer (http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi). Two CpG islands were found in whole sequence 
including island 1 (196 bp) which starts from 400 bp and ends at 595 bp and island 2 
which starts from 601 bp and ends at 1417 bp (Fig 19). 135 CpG sites were found in the 
whole sequence including 22 CpGs in promotor and 5’-UTR region and the other 113 in 
the CDS region (Fig. 27).  
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Fig. 19 CpG islands prediction of the CD14 promotor and CDS  
CDS: coding sequence 
4.10 Gene body DNA methylation of CD14 was suppressed by SFN in LPS-induced 
PAMs 
It is well known that DNA methylation plays an important role in gene regulation and 
gene expression. To further explore the epigenetic regulation of CD14 in the TRIF 
pathway in SFN-LPS treated PAMs and the molecular mechanism of SFN-induced 
repression of CD14, we analyzed the DNA methylation status of the CD14 promotor 
region and CDS (gene body) region using bisulfite sequencing. CpG islands and CpG 
sites distribution in CD14 promotor including the 5’-UTR (1- 492 bp) and CDS (493-
1694 bp) (GenBank DQ079063.1, 1762 bp of whole sequence) were predicted by using 
MethPrimer. Two CpG islands were found in the whole sequence, island 1 with a length 
of 196 bp starts from 400 bp to 595 bp and the second one from 601 bp to 1417 bp (Fig 
19). 135 CpG sites were found in the whole sequence including 22 CpGs in promotor 
and 5’-UTR region and other 113 in CDS region (Fig. 27). The CpGs in the products of 
the primers was displayed in table 7. Gene expression is suppressed by DNA 
methylation of gene promotor, but induced by gene body methylation (Huang et al. 
2014, Laurent et al. 2010). The present study showed there were no methylation 
changes in the CD14 promoter region (1-492 bp, primer 1 to 3 region) in any SFN-LPS 
treated PAMs (Fig 20A). Surprisingly, two alterations of the gene body methylation 
(CDS region) were found in sequence starting from 869 bp to 1081 bp (primer 6) and 
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from 1537 bp to 1712 bp (primer 9) in PAMs (Fig 20B). For primer 6 region, 
methylation was increased with 5 µg/ml LPS (16.7%) compared to SFN0-LPS0 (5.9%). 
On the other hand, methylation was suppressed with 5 µM SFN which showed 0% 
methylation in both SFN5-LPS0 and SFN5-LPS5 group. In LPS induced PAMs, 
methylation status of CD14 in primer 6 with both SFN5-LPS5 and SFN10-LPS5 cells 
was suppressed. Similar results were found in the primer 9 region, methylation was 
induced by LPS resulting in 25% methylation in SFN0-LPS5 PAMs but only 12.5% 
methylation in the control group. Methylation was repressed by SFN that led to 0% 
methylation in SFN5-LPS0 and SFN10-LPS0 treated cells. In LPS induced PAMs, 
demethylation was shown in SFN10-LPS5 (12.5% methylation) group but not in SFN5-
LPS5 (25% methylation) in this region.  
Table 7 CpGs in the products of primers and their positions in the original sequence 
Primer 
Sequnce sites 
(bp) 
Position Islands 
Product 
size (bp) 
CpGs in 
product 
CpG name in 
sequnce 
CD1401 20 to 188 Promotor and 5′UTR  169 6 CpG3 – CpG8 
CD1402 172 to 419 Promotor and 5′UTR  248 7 CpG9 – CpG15 
CD1403 399 to 617 
Promotor and 5′UTR; 
and exon 
Island 1 219 15 CpG16 – CpG30 
CD1404 594 to 787 Exon Island 2 194 20 CpG31 – CpG50 
CD1405 766 to 900 Exon Island 2 135 13 CpG51 – CpG63 
CD1406 869 to 1081 Exon Island 2 212 17 CpG64 – CpG80 
CD1407 1071 to 1221 Exon Island 2 151 11 CpG81 – CpG91 
CD1408 1200 to 1452 Exon Island 2 253 27 CpG92 – CpG118 
CD1409 1537 to 1712 Exon  176 8 CpG126 – CpG133 
CD1410 1428 to 1560 Exon Island 2 133 7 CpG119 – CpG125 
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Fig. 20 CD14 methylation alteration was induced by SFN in PAMs. A) Methylation 
status of the CD14 promotor and 5’-UTR region of PAMs treated with SFN (0, 5, 10 
µM) and LPS (0, 5 µg/ml). Here was no methylation alteration in CD14 promotor and 
5’-UTR. B) Methylation status of the CD14 CDS region of PAMs treated with SFN (0, 
5, 10 µM) and LPS (0, 5 µg/ml). At least 8 white cloning PCR products were used for 
sequencing, the result of one sample shown above is from at least 4 sequences (all of 
these 4 sequences show the same results). CD14 methylation in CDS (primer 6 and 
primer 9) were increased by LPS, but suppressed by SFN. Blue filled ( ) squares: un-
methylated; red filled squares ( ): methylated; open squares: unknown; Blank lines 
( ): sequence of each primer products.  
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5 Discussion  
LPS leads to inflammation in mammals through inducing the production of 
inflammatory cytokines including TNF-α and IL1-β in macrophages (Beutler and 
Cerami 1988, Carson et al. 2011, Dinarello 1991, Dobrovolskaia and Vogel 2002). 
CD14 is a PRR which binds directly to LPS and facilitates the TRIF pathway (Wright et 
al. 1990, Zanoni et al. 2011). As a HDAC inhibitor, SFN has an anti-inflammatory 
effect (Liu et al. 2008). In the present study, we demonstrated that CD14 mediated the 
LPS-induced TRIF pathway in PAMs to secrete proinflammatory and inflammatory 
cytokines. Additionaly, SFN inhibited the LPS-induced inflammation in TRIF pathway 
by regulation CD14 through epigenetic alteration. 
5.1 PAMs and their biological characters 
Phagocytosis displayed by macrophages, neutrophils and dendritic cells is an early and 
crucial event in host defense against pathogens (Henneke and Golenbock 2004). 
Macrophages are phagocytes which develop and differentiate from monocytes in the 
tissues, with pivotal functions in development, tissue remodeling, repair or homeostasis, 
host defense and inflammation (Ginhoux 2014, Gordon and Taylor 2005). They are the 
main source of cytokines, chemokines and other inflammatory mediators disseminating 
or inhibiting the immune response (Moldoveanu et al. 2009). 
PAMs are the central components of lung innate immune system (Murphy et al. 2008). 
As well known, the alveolar macrophages or PAMs are the bactericidal functionalities 
of the lungs (Green and Kass 1964). The basic biologic knowledge of PAMs like cell 
growth, the inherent half-life, cell apoptosis are the premise of the PAMs’ functional 
study. A half-life of 2 weeks (Godleski and Brain 1972) and 30 days (Matute-Bello et 
al. 2004) for PAMs has been shown. In this study, PAMs were observed growing in a 
time dependent manner. Viable growth of PAMs was shown between day 3 to day 18. 
At day 29, most of the cells were degenerated. Thus, the time point of day 9 was chosen 
for LPS treatment and day 7 was chosen for SFN pretreatment.  
Cell markers can be used for recognizing and sorting cell types. The typical macrophage 
markers are CD11b and D163. CD13 is a marker of mature resident macrophages 
related to secretion of inflammatory mediators (Dimitrijevic et al. 2013, Held et al. 
2013). Flow cytometry and cell sorters were developed aiming to characterize single-
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cells, due to cell physical and chemical properties. The principle of the method is based 
on the laser path. It measures the single-cells in liquid suspension by passing them 
through an electronic detection apparatus (Metes et al. 2003). In this study, it was 
shown that 35% of the PAMs were stained with the cell marker CD163 (PAMs without 
SFN and LPS treatment) by using flow cytometry.   
5.2 Cell viability of PAMs with LPS/ SFN-LPS challenge 
Cell viability is used for cell vitality and chemical cytotoxicity tests. The enzyme-based 
WST method relies on a reductive coloring reagent and dehydrogenase in a viable cell 
to determine cell viability. Cell viability is effected by the cell culture density (Zhuang 
and Wogan 1997) and experimental chemical concentration.  
In this study, PAMs were cultured with a density of 1 * 105 cells/well. LPS at a dose of 
5 µg/ml was used to induce inflammatory conditions in cultured PAMs. We showed that 
LPS treatment had no notable effect on the cell viability at all the 7 time points 
compared with the control.  
Factors like extract of Glycyrrhiza glabra L. (EGGR) and SFN can affect cell viability. 
EGGR (100 μg/ml) increased cell viability (from 66.6 to 99%) of LPS-treated 
macrophages (Li et al. 2015). SFN (5 μM) pre-treatment enhanced cell viabilities of 
cytotoxicity of cadmium selenide (CdSe) quantum dots (QDs)-treated liver cells in mice 
(Wang et al. 2015). It was also shown that pre-treatment with SFN increased cell 
viability by decreasing intracellular reactive oxygen species production (Ziaei et al. 
2013). In this study, SFN (5, 10 µM) pre-treatment increased LPS-treated PAMs cell 
viability.  
5.3 CD14 mRNA and downstream TRIF pathway genes expression were induced by 
LPS  
Inflammation is the body’s reaction to defend against pathogens (Ferrero-Miliani et al. 
2007, Moldoveanu et al. 2009). LPS is the major structural component of the outer wall 
of gram-negative bacteria. It is a potent initiator of inflammatory responses. Therefore, 
LPS is important in lung inflammation and is regularly used as a model for pulmonary 
inflammation. Cytokines, the nonstructural and small proteins with molecular weights 
ranging from 8 to 40,000 d, are primarily involved in host responses to disease or 
infection like inflammation (Dinarello 2000). They are the marker and regulators 
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(promoters or suppressors) of the inflammation. In the LPS-TRIF pathway, TRAF6 
activated the release of the pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, 
IL-12, while TRAF3 initiated the production of IFN-α and IFN-β (Fig. 4). 
LPS increased IL-8 release in a human macrophage-derived cell line (THP-1) cells at a 
concentration of 10 μg/ml after 24 h of incubation (Antonicelli et al. 2004). LPS 
treatment also increased TLR2 mRNA expression in a mouse macrophage cell line 
(Matsuguchi et al. 2000). It is known to cause inflammation in mammals through 
induction of the production of inflammation cytokines such as TNF-α and IL1-β in 
macrophages (Beutler and Cerami 1988, Carson et al. 2011, Dinarello 1991, 
Dobrovolskaia and Vogel 2002). LPS injection in mice upregulated the levels of LBP, 
CD14, TNF-α, IL-6 and IFN-γ in spleen (Zhang et al. 2015). LPS induced 
phosphorylation of IRF3 and the activation of the TRIF signaling pathway in monocytes 
(Endo et al. 2014).  
CD14 is an acute phase inflammatory biomarker. It is the PRR binding directly to LPS 
and facilitates TRIF pathway (Wright et al. 1990, Zanoni et al. 2011). CD14 was 
necessary for the microbe-induced endocytosis of TLR4 while CD14 controls the 
trafficking and signalling functions of TLR4. This innate immune trafficking cascade 
illustrates how pathogen detection systems operate to induce both membrane transport 
and signal transduction (Zanoni et al. 2011). In a CD14-dependent manner, soluble-
lipopolysaccharide (S-LPS) and rough lipopolysaccharide (R-LPS) at low dose induced 
acute lung inflammation, while the inflammatory response triggered by high dose S-
LPS or R-LPS was reduced by CD14 (Anas et al. 2010). 
CD14 expression is essential for the development of LPS-induced systemic 
inflammation and for activation of circulating neutrophils, but not necessary for the 
mechanism of LPS detection and activation of neutrophil recruitment in the liver 
microcirculation (McAvoy et al. 2011). LPS induces CD14-TLR4 pro-inflammatory 
signaling through triggering the generation of phosphatidylinositol 4, 5-bisphosphate 
[PI (4, 5) P2]. It was shown that LPS induced a CD14-dependent immobile fraction of 
TLR4 in the plasma membrane (Klein et al. 2015). This is in accordance with previous 
findings that CD14 mRNA expression was induced by LPS in alveolar macrophage of 
pigs (Islam et al. 2013). Exposure of alveolar macrophages to LPS (0.1, 1, 5, 10 µg/ml) 
increased CD14 expression compared with control (Islam et al. 2013). In this study, we 
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found that CD14 gene expression was significantly increased by 5 µM LPS treatment at 
time point 12 h.  
It was shown that LPS initiates the TRIF pathway independent of CD14 (Watanabe et 
al. 2013), but CD14 is also required for the TRIF-independent signaling (Jiang et al. 
2005, Lloyd-Jones et al. 2008, Regen et al. 2011). In the TRIF pathway, TRIF activates 
both TRAF3 and TRAF6 by a binding domain present on its N-terminus (Brown et al. 
2011, Wang et al. 2001, Yamamoto et al. 2003a, Yamamoto et al. 2003b). The 
activation of TRAF6 initiates NF-κB signaling which leads to the release of the pro-
inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-12 (Fig. 4) and the activation 
of TRAF3 initiates IRF-3 through IKKi and TBK-1, then the phosphorylation of IRF3 
induces the production of IFN-β (Brown et al. 2011, Doyle et al. 2002). TRAF3 
regulates the production of anti-inflammatory cytokine IL-10 and the activation of the 
IFN (Hacker et al. 2006). It was shown that CD14 is required for LPS-induced 
activation of the TLR4/TRAM-TRIF pathway even at very high LPS doses. Both 
smooth and rough LPS cannot induce TRAM-TRIF-dependent IRF3 activation and 
type-I IFN production without CD14 (Jiang et al. 2005). In this study, similar as CD14, 
the mRNA expression of the downstream genes including TRIF, TRAF6, NFκB, 
TRAF3 and IRF7 also was also enhanced by LPS.  
Cytokine genes like IL-6, IL-8 and TNF-α are immune associated genes with strong 
response to LPS (Green and Kerr 2014). TNF-α mRNA expression was induced by LPS 
(Green and Kerr 2014). LPS induced the release of IL1-β, IL12-β, TNF-α, IL-6, IL-8, 
IFN-γ and IL-10 in a dose-dependent manner in pig macrophages (Islam et al. 2013). In 
this study, the mRNA expression of inflammatory cytokines including TNF-α, IL-1β, 
IL-6 and IFN-β were upregulated in LPS stimulated PAMs.  
5.4 mRNA expression of CD14 and downstream LPS-induced TRIF pathway genes 
were suppressed by SFN in a dose dependent pattern 
Epigenetic control including the DNA methylation and histone acetylation may play a 
crucial role in the revision of immune-responsive genes related to pathogen recognition 
and subsequent signaling (Green and Kerr 2014). Recent research presented chemical 
inhibitors such as 5-aza-2-deoxycytidine (AZA), trichostatin A (TSA) and SFN as 
epigenetic modifiers (Luo et al. 2015, Samiec et al. 2015, Su et al. 2014, Yang et al. 
2014). As a HDAC inhibitor, SFN also has anti-proliferative, pro-apoptotic role in 
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cancer cells (Chu et al. 2009, Ho et al. 2009) and anti-inflammatory activity (Ko et al. 
2013, Koo et al. 2013). SFN regulates LPS-induced innate immune responses of porcine 
moDCs (Qu et al. 2015). In this study, we found that SFN suppresses the gene 
expression of CD14 and it’s down stream genes including TRAM, TRIF, RIPK1 and 
TRAF3 in the TRIF pathway.  
Our results suggest that SFN possesses anti-inflammatory activity, resulting in 
downregulation of LPS-induced CD14, TRAM, TRIF, RIPK1 and TRAF3 in 
macrophages in pigs. 
5.5 LPS-induced inflammatory cytokines and NF-κB were suppressed by SFN in a 
dose dependent manner in PAMs 
Pro-inflammatory cytokines such as IL-1 and TNF-α play critical roles in the progress 
of diseases including cancer (Guo et al. 2012). They are the Th1 cytokines to produce 
the pro-inflammatory responses to fight viruses and other intracellular parasites and to 
eliminate cancer cells (Moldoveanu et al. 2009). TNF-α concentration in the cell 
supernatant fluid increased immediately at 1 h after LPS stimulation (Islam et al. 2012). 
NF-κB is connected with cancer, inflammatory and autoimmune diseases due to its role 
in modulating transcription of DNA, cytokine production and cell survival (Gilmore 
2006). 
Inflammation balance is one of important strategies for the prevention and treatment of 
diseases. Factors like nacystelyn (NAL) can modulate the LPS-induced inflammation. 
NAL decreased IL-8 release from LPS-stimulated THP-1 cells after 4 h of incubation 
(Antonicelli et al. 2004). LPS-induced mammary gland histopathologic changes, NF-κB 
and MAPKs activations and TNF-α, IL-1β and IL-6 production were inhibited by 
TRAM-derived decoy peptide (TM6) in mice (Zhang et al. 2015). EGGR suppressed 
LPS-induced iNOS, COX-2 cytokines, TNF-α, IL-1β and IL-6 at both the mRNA and 
the protein level (Li et al. 2015). ADP-ribosylation factor 6 (ARF6) reduced LPS-
induced cytokine production and regulated TRAM/TRIF-dependent TLR4 signaling in 
mouse macrophages (Van Acker et al. 2014). TF5 (a peptide derived from putative helix 
B of TRIF TIR) downregulated plasma cytokine levels and protected mice from a fatal 
LPS challenge in a mouse model of TLR4-driven inflammation (Piao et al. 2013). 
Mammalian peroxiredoxin V (PrdxV), a multifunctional protein which inhibits stress-
induced apoptosisis and protects cells from DNA damage, is the key mediator 
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contributing to the regulation of LPS/TLR4-induced immune responses. It selectively 
regulates IL-6 production by modulating the Jak2-Stat5 pathway (Choi et al. 2013).  
Epigenetic control including the DNA methylation and histone acetylation may play a 
crucial role in the regain of immune-responsive genes related to pathogen recognition 
and subsequent signaling (Green and Kerr 2014). Recent research presented chemical 
inhibitors such as 5-aza-2-deoxycytidine (AZA), trichostatin A (TSA) and SFN to be 
epigenetic modifiers (Fan et al. 2012, Luo et al. 2015, Samiec et al. 2015, Su et al. 2014, 
Yang et al. 2014).  
As a HDAC inhibitor, SFN also has anti-proliferative and pro-apoptotic roles in cancer 
cells (Chu et al. 2009, Ho et al. 2009) and anti-inflammatory activity (Ko et al. 2013, 
Koo et al. 2013). SFN showed a potent decrease in LPS-induced secretion of pro-
inflammatory and pro-carcinogenic signaling factors in cultured Raw 264.7 
macrophages (Heiss et al. 2001). SFN regulated the LPS-induced innate immune 
responses of porcine monocyte-derived dendritic cells (moDCs) though epigenetic 
mechanisms (Qu et al. 2015). SFN suppressed the LPS-induced secretion of 
inflammatory mediators like TNFα, IL-1β and IL-6 (Heiss et al. 2001, Wierinckx et al. 
2005). Low doses of SFN and NBN significantly reduced LPS-induced IL-1 mRNA 
expression (Guo et al. 2012).  
In this study, we found that SFN suppressed the mRNA expression of LPS-dependent 
inflammatory cytokines including TNFα, IL-1β, IL-6 and IFNβ in a dose dependent 
manner. In addition, the protein level of TNFα and IL-1β also were suppressed by SFN. 
Further, the protein level of NF-κB was inhibited by SFN. 
Taken together, our data indicate that SFN possesses anti-inflammatory activity, 
resulting in downregulation of LPS-stimulated TNFα, IL-1β, IL-6, IFNβ and NF-κB in 
porcine macrophages. 
5.6 DNMT3a gene expression was induced by LPS but suppressed by SFN 
It is well known that DNMT1 is the key maintenance methyltransferase, whereas 
DNMT3a and DNMT3b play the role in de novo activity (Robertson et al. 2000, 
Ronemus et al. 1996). Knockdown of the DNMT1 gene reduced the suppressors of 
cytokine signaling1 (SOCS1) gene promoter methylation and upregulated the 
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expression of SOCS1 in activated RAW264.7 cells (Cheng et al. 2014). DNMT1 
inhibited SOCS1 expression though the SOCS1 hypermethylation, that caused the 
suppression of the activation of the JAK2/STAT3 pathway and enhanced the level of 
LPS-induced pro-inflammatory cytokines such as TNF-α and IL-6 in macrophages 
(Cheng et al. 2014). Liver cells and spleen cells responded to exposure of LPS with 
alterations in proteins levels involved in DNA methylation (DNMT1, DNMT3a and 3b) 
or DNA repair with changes in gene expression (Kovalchuk et al. 2013a, Kovalchuk et 
al. 2013b).  
LPS induced NF-κB activation and decreased levels of histone HDAC1 and DNMTs 
(Biswas and Yenugu 2013). DNMT1 mRNA expression was significantly increased by 
LPS treatment in fibroblasts derived from human periodontal ligament (HPDL) (Uehara 
et al. 2014). LPS downregulated DNMT1 (p < 0.05) gene expression in HaCaT cells (de 
Camargo Pereira et al. 2013), the same result was found in our study. It was shown that 
DNMT3a gene expression was downregulated in response to LPS in PBMCs (Doherty 
et al. 2013). However, the DNMT3a gene expression was increased by LPS in this 
study.  
SFN inhibited LPS-induced DNMT3a, HDAC6 and HDAC10 gene expression, whereas 
it upregulated DNMT1 gene expression (Qu et al. 2015). SFN extremely decreased the 
protein expression of DNMT1, DNMT3a and DNMT3b (Su et al. 2014). SFN also 
downregulated the protein levels of DNMT1, DNMT3a, HDACs 1, 4, 5 and 7 while 
increased the level of active chromatin marker acetyl-Histone 3 (Ac-H3) in prostate 
cancer TRAMP C1 cells (Zhang et al. 2013). DNMT1 and DNMT3a were decreased in 
SFN-treated breast cancer cells suggesting that SFN may inhibit human telomerase 
reverse transcriptase (hTERT) by affecting epigenetic pathways. SFN inhibited the LPS 
induced HDAC6, HDAC10 and DNMT3a gene expression while upregulated the 
expression of DNMT1 gene (Qu et al. 2015).  
In the present study we found SFN reduced DNMT1 and DNMT3a mRNA expression 
in a dose dependent manner. Like CD14 gene, DNMT3a gene expression was increased 
by LPS and suppressed significantly by SFN at the dose of 5 µM. This result suggests 
that CD14 DNA methylation changes may be related with DNA methylation enzyme 
DNMT3a in PAMs.  
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Take together, CD14 may be involved in the TRIF pathway and the suppression of LPS-
induced CD14 gene expression was associated with the suppression of CD14 gene body 
methylation which may be caused by downregulation of DNMT3a gene expression in 
PAMs post SFN pre-treatment.  
5.7 Gene body DNA methylation of CD14 was suppressed by SFN in LPS-induced 
PAMs 
DNA methylation is a critical epigenetic modification in mammals (Huang et al. 2014). 
It refers to the addition of methyl groups to the adenine or cytosine bases of DNA and is 
tightly associated with gene regulation (Plongthongkum et al. 2014, Wilson et al. 2014). 
Over the past years, most studies showed that DNA methylation modification occurs in 
gene promoter to be a key molecular mechanism leading to gene expression changes 
(Curradi et al. 2002, Gao et al. 2007, Kontorovich et al. 2009, Park et al. 2012). 
Although the promoter DNA methylation is known as a silencing mechanism, the gene 
body has recently been recognized as a major mechanism for regulating gene expression 
in many tissues (Baylin and Jones 2011).  
Recently, some studies demonstrated that DNA methylation in the gene body is 
connected with gene expression (Fan et al. 2015, Sarda et al. 2012, Wang et al. 2013, 
Yang et al. 2014). DNA methylation in the gene body region can alter gene expression 
and is a therapeutic target in cancer (Yang et al. 2014). The high densities of 
hypomethylated CpG-rich regions across the gene body are preferentially associated 
with gene downregulation (Yu et al. 2015). Although several recent studies investigated 
the role of gene body DNA methylation on gene expression, the function of gene body 
DNA methylation is poorly understood (Kulis et al. 2012, Lister et al. 2009, Lou et al. 
2014, Maunakea et al. 2010, Varley et al. 2013).  
In an attempt to identify potential epigenetic changes which mediate the effect of SFN 
on CD14 expression, we further assessed the methylation status of CpG islands 
embedded in the CD14 promotor and the whole CDS region. Surprisingly, our results 
showed that there were no methylation changes in the CD14 promotor of non CpG 
island and also CpG island regions, but methylation alterations were found in the CD14 
CDS region (Fig. 20B). The results showed that CD14 gene body methylation was 
induced by 5 µM LPS in PAMs (Fig. 20B, primer 6 and primer 9 region). Therefore, 
gene expression of CD14 was increased in LPS treatment cells. Theses results showed 
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that gene body DNA methylation was positively connected with CD14 gene expression. 
Similarly, research suggested that gene body DNA methylation may increase 
transcriptional activity by blocking the initiation of intragenic promoters or by affecting 
the activities of repetitive DNAs within the transcriptional unit (Maunakea et al. 2010).  
However, CD14 gene body methylation was also decreased by the HDAC inhibitor 
SFN. Results showed that CD14 gene body methylation was inhibited by both 5 µM 
SFN and 10 µM SFN (Fig 20B, primer 6 and primer 9 region). It might be considered 
that the CD14 gene expression was suppressed by SFN depending on the methylation 
inhibition of CD14 gene body in LPS-induced PAMs. Gene body DNA demethylation 
induced-gene repression may be due to 3 factors including: 1) whether embedded 
demethylated functional elements regain activity, 2) whether demethylated regions are 
located at intron-exon junctions together with destabilized nucleosomes, 3) possible 
effects on the rates of transcript elongation and splicing (Yang et al. 2014).  
In summary, CD14 acts not only as a LPS-receptor, but also as a LPS-induced 
inflammation regulator that mediates the TRIF pathway genes and cytokines expression. 
This regulatory role of CD14 may depend on the epigenetic changes in gene body 
methylation caused by SFN. In addition, this DNA methylation alteration is probably 
related with DNMT3a expression. The SFN-mediated inhibition of DNMTs especially 
DNMT3a could be an important contributing factor in CD14 DNA methylation 
regulation and also in the SFN anti-inflammation role. 
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6 Summary 
Infections of the respiratory system which cause diseases like lung inflammation are main 
threats in pig production. LPS is the component of the outer membrane of gram-negative 
bacteria and one of the most predominant microbial stimulators of inflammation. The 
innate immunity system can recognize and response to bacteria. PAMs constitute a vital 
component of the alveolar spaces and play a central role in pulmonary innate immunity and 
functionally work in LPS-induced lung inflammation. Two pathways including the 
MyD88-dependent and MyD88-independent (TRIF) pathways are activated after TLR4 
stimulation with LPS. CD14 is the PRR which binds directly to LPS, transfers LPS 
molecules in a co-expressed way to TLR4 and initates the MyD88-dependent and TRIF 
pathways. Therefore, CD14 may be involved in TRIF pathway cytokines release and 
downstream genes expression.  
As an epigenetic regulator, SFN was also shown to have an anti-inflammation role. 
Therefore, SFN may inhibit the LPS-induced inflammation through regulation of CD14 
gene expression. The epigenetic modulation including DNA methylation and histone 
modulation of CD14 in response to infection are poorly understood. In the present study, 
we identified the epigenetic changes of CD14 mediated with SFN in LPS-induced TRIF 
pathway with an in vitro PAMs model in pig. The methylation status of CpG islands 
embedded in the CD14 promotor and whole CDS region was analyzed. 
We found that CD14 gene expression was significantly increased by 5 µM of LPS 
treatment at 12 h. Likewise, the mRNA expression of the downstream genes TRIF, 
TRAF6, NFƳB, TRAF3 and IRF7 were also upregulated significantly. In addition, the 
mRNA expression of inflammatory cytokines including TNF-α, IL-1β, IL-6 and IFN-β 
were significantly upregulated in LPS stimulated PAMs. It is important to point out that 
CD14 mediates the TRIF signals and induced the inflammatory cytokines in LPS 
challenged PAMs. 
SFN inhibited the gene expression of CD14 and its downstream genes including TRAM, 
TRIF, RIPK1, TRAF3 and IRF7 that are involved in TRIF pathway to recognize 
LPS/bacteria. In addition, SFN also downregulated the protein level of LPS-induced 
inflammatory cytokines including TNFα, IL-1β, IL-6 and IFNβ in a dose dependent 
manner.  
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The CD14 DNA methylation results showed that there was no methylation change 
occurring in the CD14 promotor either in non CpG islands or in CpG islands, but 
methylation alterations were found in CD14 CDS region. Results showed that CD14 gene 
body methylation was induced by 5 µM of LPS in PAMs. Therefore, gene expression of 
CD14 was increased in LPS treated PAMs. Theses results showed that gene body DNA 
methylation was positively connected with CD14 gene expression. However, CD14 gene 
body methylation was decreased by SFN. Results presented that CD14 gene body 
methylation was inhibited by both 5 µM SFN and 10 µM SFN. The surprising result from 
our study is that gene body regions show sustained DNA demethylation and gene 
downregulation of expression after SFN withdrawal. It might be considered that the CD14 
gene expression suppressed by SFN is depending on the methylation inhibition of CD14 
gene body in LPS-induced PAMs. Therefore, CD14 plays a role not only as a LPS-
receptor, but also as a LPS-induced inflammation regulator that mediates the TRIF 
pathway genes and cytokines expression and also cytokines secretion through the 
epigenetic changes in gene body methylation by SFN in PAMs.  
Another important outcome of this study is that CD14 DNA methylation changes may be 
related to expression of DNA methylation enzyme DNMT3a. We found that SFN 
downregulated DNMT3a mRNA expression in a dose dependent manner. It is suggested 
that CD14 is involved in the TRIF pathway in PAMs. The repression of LPS-induced 
CD14 gene expression was associated with the CD14 gene body demethylation which 
might be caused by DNMT3a gene suppression due to SFN regulation. 
In summary, in the present in vitro study, we have demonstrated not only that CD14 is 
involved in the TRIF pathway by LPS treatment in a time dependent manner, but also 
explored the possible epigenetic mechanism such as demethylation in the gene body region  
related to CD14 repression in SFN pre-treated PAMs. In addition, this DNA methylation 
alteration is probably related with DNMT3a expression. This study provided new insights 
into SFN-mediated epigenetic downregulation of CD14 gene in LPS induced-TRIF 
pathway inflammation. It may open new methods to prevent and reduce the LPS-induced 
inflammation in pigs. 
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Zusammenfassung 
Infektionen der Atemwege, die zu Krankheiten wie Lungenentzündung führen, sind eine 
der Hauptbedrohungen in der Schweineproduktion. LPS als Komponente der äußeren 
Membran von gramnegativen Bakterien ist einer der vorherrschenden mikrobiellen 
Stimulatoren für Entzündungen. Das angeborene Immunsystem kann schnell solche 
Entzündungen erkennen und darauf reagieren. PAMs bilden eine wichtige Komponente der 
Alveolarräume und spielen daher eine zentrale Rolle in der angeborenen pulmonalen 
Immunabwehr sowie bei der funktionellen Arbeit durch LPS-induzierte 
Lungenentzündung. Zwei wesentliche Signalwege, MyD88-abhängig und MyD88-
unabhängig (TRIF) werden aktiviert, nach der Stimulation von TLR4 durch LPS. CD14 ist 
der PRR, der direkt an LPS bindet, die LPS-Moleküle zum TLR4 transportiert und dadurch 
die MyD88-abhängigen und den TRIF-Signalweg initiiert. Daher scheint CD14 an der 
Freisetzung von TRIF Signalweg-Zytokinen und an der Expression von nachgeschalteten 
Genen beteiligt zu sein. 
 
Als epigenetische Regler hat SFN eine entzündungshemmende Wirkung. Daher ist die 
Frage, ob SFN die LPS-CD14-induzierte Entzündung durch Regulierung der CD14 
Genexpression hemmen kann, von Interesse. Allerdings ist das Verständnis der 
epigenetischen Modulationen einschließlich DNA-Methylierung und Histon-Modifikation 
von CD14 in Bezug auf die Reaktion auf eine Infektion gering. In der vorliegenden Studie 
haben wir daher die epigenetischen Veränderungen von CD14 durch SFN in LPS-
induziertem TRIF Signalweg mit einem in vitro-Modell in PAMs beim Schwein, 
untersucht. Um potentielle Veränderungen des DNA-Methylierungsstatus zu identifizieren, 
die mit der Wirkung von SFN auf die CD14-Expression assoziiert sind, wurde der 
Methylierungsstatus der CpG Inseln sowohl der CD14-Promotor Region als auch der 
intragenetic Region (CDS Region) analysiert. 
 
Es konnte festgestellt werden, dass die CD14 Genexpression signifikant in Zellen mit 5 
µM LPS nach 12 h erhöht war. Ebenfalls war die mRNA-Expression der nachgeschalteten 
Gene, TRIF, TRAF6, NFƳB, TRAF3 und IRF7, hochreguliert. Des Weiteren, ergab die 
mRNA-Expressionsanalyse der Zytokine, TNF-α, IL-1β, IL-6 und IFN-β, ebenfalls eine 
Hochregulation in LPS stimulierten PAMs. Es ist wichtig darauf hinzuweisen, dass CD14 
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die TRIF Signale vermittelt und die inflammatorischen Zytokine in LPS behandelten 
PAMs induziert. 
 
Durch die Zugabe von SFN wurde die Genexpression von CD14 und den nachgeschalteten 
Genen, TRAM, TRIF, RIPK1, TRAF3 und IRF7, die im TRIF Signalweg an der 
Erkennung von LPS/Bakterien beteiligt sind, gehemmt. Weiterhin, unterdrückt SFN die 
Produktion von LPS-induzierten inflammatorischen Zytokinen, TNFα, IL-1β, IL-6 und 
IFN-ß, in Abhängigkeit von der Dosis. 
 
Die Analyse des Methylierungsprofils ergab überraschenderweise, dass es keine Änderung 
des Methylierungsstatus in der CD14-Promotor Region gab, weder in CpG-Inseln noch 
außerhalb von CpG-Inseln. Allerdings zeigte sich eine Veränderung des 
Methylierungsbildes in der intragenic Region des CD14 Gens. Die Ergebnisse ergaben, 
dass eine Behandlung mit 5 µM LPS die CD14-Methylierung induziert. Daher war die 
Genexpression von CD14 LPS behandelten PAMs erhöht. Diese Ergebnisse zeigten, dass 
die Gen intragenic Region Methylierung positiv mit der CD14 Genexpression assoziiert ist. 
Jedoch wurde die CD14 Methylierung durch SFN wieder gesenkt. Die inragenic Region 
Methylierung von CD14 war sowohl bei 5 µM SFN als auch 10 µM SFN gehemmt. Das 
überraschende Ergebnis unserer Studie ist, dass die Gen inragenic Region eine klare DNA 
Demethylierung zeigt und das eine Herunterregulation der Genexpression nach SFN 
Behandlung beobachtet werden kann. Es könnte daher in Betracht gezogen werden, dass 
die CD14-Gen-Expression, unterdrückt durch SFN, abhängt von der 
Methylierungshemmung der CD14-Gen intragenic Region in LPS-induzierten PAMs. 
Deshalb spielt CD14 nicht nur eine Rolle als LPS-Rezeptor, sondern auch als eine Art 
LPS-induzierter Entzündungsregler, der die TRIF Signalweg-Gene, die Zytokin-
Expression und auch die Zytokin-Sekretion durch die epigenetischen Veränderungen in der 
inragenic Region Methylierung durch SFN in PAMs vermittelt. 
 
Eine weitere wichtige Entdeckung dieser Studie ist, dass die Veränderungen des CD14 
DNA-Methylierungsstatus im Zusammenhang mit der Expression des DNA-
Methylierungs-Enzyms DNMT3a stehen. Es konnte festgestellt werden, dass SFN die 
DNMT3a mRNA-Expression in Abhängigkeit von der Dosis herunterreguliert. Daraus 
ergibt sich, dass CD14 in den TRIF Signalweg involviert zu sein scheint und daher die 
Hemmung der LPS-induzierten CD14 Genexpression mit der CD14 intragenic Region 
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Methylierung assoziiert ist, die durch die Herrunterregulation der DNMT3a Genexpression 
in PAMs aufgrund der SFN Vorbehandlung verursacht sein könnte. 
 
Zusammenfassend konnten wir in dieser in vitro Studie nicht nur zeigen, dass CD14 am 
TRIF Signalweg nach einer LPS-Behandlung im Zeitverlauf beteiligt ist, sondern auch der 
mögliche epigenetische Mechanismus wie Demethylierung in der intragenic Region in 
Verbindung mit der Repression von CD14 in SFN behandelten PAMs steht. Darüber 
hinaus wird diese DNA Methylierungsänderung wahrscheinlich mit der DNMT3a 
Expression assoziiert sein. Diese Studie gibt einen neuen Einblick in die SFN-vermittelten 
epigenetischen Herunterregulationen des CD14-Gens in LPS induzierten TRIF Signalweg 
Entzündungen. Dadurch ergeben sich neue Wege zur Entwicklung von neuen Ansätzen zur 
Vermeidung bzw. Milderung von LPS-induzierten Entzündungen bei Schweinen. 
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Fig. 21 (Appendix 1) The role of LPS and SFN on gene expression regulation of CD14 
and downstream genes in PAMs. A) CD14 and downstream genes TRAM and TRIF 
mRNA expression in SFN-LPS stimulated PAMs. B) TRIF-TRAF6 pathway genes 
mRNA expression in SFN-LPS treated PAMs. C) TRIF-TRAF3 pathway genes mRNA 
expression in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) for 24 h 
treatment and LPS (5 µg/ml) for 12 h treatment were used in this assay. Fold change in 
PAMs without SFN and without LPS treatment (SFN0-LPS0) was set as control. 
Comparison between treatment group (black column) and control group (white column) 
is indicated as ‘*’. All of the data were expressed as least square means ± SE, n = 3. *, 
** and *** indicate significant differences at p < 0.05, p < 0.01 and p < 0.001, 
respectively. 
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Fig. 22 (Appendix 2) Effect of SFN5 and SFN10 on gene expression regulation of 
CD14 and downstream genes in PAMs. A) CD14 and downstream genes TRAM and 
TRIF mRNA expression in SFN-LPS stimulated PAMs. B) TRIF-TRAF6 pathway 
genes mRNA expression in SFN-LPS treated PAMs. C) TRIF-TRAF3 pathway genes 
mRNA expression in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) 
for 24 h treatment and LPS (5 µg/ml) for 12 h treatment were used in this assay. All of 
the data were expressed as least square means ± SE, n = 3. *, ** and *** indicate 
significant differences at p < 0.05, p < 0.01 and p < 0.001, respectively. 
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Fig. 23 (Appendix 3) The role of LPS and SFN on gene expression regulation of 
cytokines in the TRIF pathway in PAMs. A) Relative gene expression of TRIF-TRAF6 
pathway released cytokines in SFN-LPS treated PAMs B) Relative gene expression of 
TRIF-TRAF3 pathway released cytokines in SFN-LPS treated PAMs. PAMs with or 
without SFN (5, 10 µM) for 24 h treatment and LPS (5 µg/ml) for 12 h treatment were 
used in this assay. Fold change in PAMs without SFN and without LPS treatment 
(SFN0-LPS0) was set as control. Comparison between treatment group (black column) 
and control group (white column) is indicated as ‘*’. All of the data were expressed as 
least square means ± SE, n = 3. *, ** and *** indicate significant differences at p < 
0.05, p < 0.01 and p < 0.001, respectively. 
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Fig. 24 (Appendix 4) Effect of SFN5 and SFN10 on gene expression regulation of 
cytokines in the TRIF pathway in PAMs. A) Relative gene expression of TRIF-TRAF6 
pathway released cytokines in SFN-LPS treated PAMs B) Relative gene expression of 
TRIF-TRAF3 pathway released cytokines in SFN-LPS treated PAMs. PAMs with or 
without SFN (5, 10 µM) for 24 h treatment and LPS (5 µg/ml) for 12 h treatment were 
used in this assay. Comparison between treatment group and control group is indicated 
as ‘*’. All of the data were expressed as least square means ± SE, n = 3. *, ** and *** 
indicate significant differences at p < 0.05, p < 0.01 and p < 0.001, respectively. 
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Fig. 25 (Appendix 5) The role of LPS and SFN on gene expression regulation of 
DNMT1 and DNMT3a. Relative DNMT1 and DNMT3a gene expression were 
measured in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) for 24 h 
treatment and LPS (5 µg/ml) for 12 h treatment were used in this assay. Fold change in 
PAMs without SFN and without LPS treatment (SFN0-LPS0) was set as control. 
Comparison between treatment group (black column) and control group (white column) 
is indicated as ‘*’. All of the data were expressed as least square means ± SE, n = 3. * 
indicates significant difference at p < 0.01. 
 
Fig. 26 (Appendix 6) Effect of SFN5 and SFN10 on gene expression regulation of 
DNMT1 and DNMT3a. Relative DNMT1 and DNMT3a gene expression were 
measured in SFN-LPS treated PAMs. PAMs with or without SFN (5, 10 µM) for 24 h 
treatment and LPS (5 µg/ml) for 12 h treatment were used in this assay. Comparison 
between treatment group and control group is indicated as ‘*’. All of the data were 
expressed as least square means ± SE, n = 3. ** indicates significant difference at p < 
0.01. 
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Fig. 27 (Appendix 7) Sequence, CpG sites and bisulfite primers of CD14 promoter and 
CDS.  
Note: Upper row: Original sequence; Lower row: Bisulfite modified sequence, for 
display, assume all CpG sites are methylated; ++ CpG sites; :::: Non-CpG 'C' converted 
to 'T'; >>>>>> Left  primer; <<<<<< Right primer 
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Fig. 28 (Appendix 8) Protein levels of CD14 in SFN-LPS treated PAMs 
 
 
Fig. 29 (Appendix 9) Protein levels of Ac-H3 and Ac-H4 in SFN-LPS treated PAMs 
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Prastowo Sigit, Dr. Xueqi Qu, Mr. Aminul Islam, Ms. Sharmin Aqter Rony, Mr. Samuel 
Etay, Mr. Zidane, Mohammed, Mr. Eryk Andreas, Mr. Hari Om Pandey, Ms. Julia 
Welzenbach and Ms. Esther Heuß.  
Thanks my dear Chinese friends here for helping me and encourage my in these years. I 
want to thanks Mr. Rui Zhang, Mr. Fangjun Zhu, Mr. Huitao Fan and his wife Xiaoli 
Qi, Ms. Lijie Liu, Ms. Huanhuan Tai, Ms. Xinxin Du, Ms. Yingying Zhao and Ms. 
Xiaomei chen.  
I sincerely appreciate China Scholarship Council (CSC) for providing me financial 
support during my study period. 
I owe deepest gratitude to my parents, my dear sister, my brother and my whole family 
for help and support throughout the years and my life. I also would like to thank Mr. 
Henkel and his family for their love, care and help during the years.   
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►Personal information 
Family Name:    Yang 
First Name:    Qin 
Gender:    female 
Date of Birth:    
Country of Birth:    China 
Nationality:    Zang Minority (Tibetan)  
First Language:    Mandarin 
Second Language:    English 
Marital status:    
►Educational background 
Ph.D study  Major in Animal Science, Sep 2011-present, Dept. of Animal Breeding 
and Husbandry, Institute of Animal Science, University of Bonn, Germany, Title of 
research: Epigenetic regulation on CD14 in TRIF pathway in alveolar macrophages of 
German Landrace Pigs 
M. S.  Major in Animal Genetics and Breeding, Sep 2008-Jul 2011, Institute of Animal 
Genetics and Breeding, Sichuan Agricultural University, P. R. China, Title of the thesis: 
“ELOVL2 and ELOVL5 Gene Cloning and The Expression in Different Tissues in 
Erlang Mountainous chicken in Different Feeding Methods” 
B. S.  Major in Animal Science, Sep 2004-Jul 2008, Sichuan Agricultural University, 
P.R. China 
Middle school study   Sep 1998-Jun 2004, Liang Shan National Middle school, P.R. 
China 
Primary school study  Sep 1992-Jun 1998, Li Zhuang village primary school, P.R. 
China 
►Work experience 
Sep 2011-present 
Major in Animal Science, Dept. of Animal Breeding and Husbandry, Institute of 
Animal Science, University of Bonn, Germany. Title of research: Epigenetic regulation 
on CD14 in TRIF pathway in alveolar macrophages of German Landrace Pigs 
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Jul 2008-July 2011 
Worked as a research fellow (as a student for M.S.) in institute of Animal Genetics and 
Breeding (Sichuan Agricultural University). Our research work was focused on 
breeding a high-quality chicken breed Erlang Mountainous chicken and my thesis is a 
study on elongation of very long-chain fatty acids (ELOVL) members. 
Mar 2008-Jun 2008 
Practiced chicken breading in Sichuan Daheng Poultry Breeding Company, Ltd. 
Sep 2004-Mar 2008 
Study fellow (as a student for BS degree) in College of Animal Science and 
Technology, Sichuan Agricultural University.  
Laboratory and software skills: Cell culture (culture innate immune cell - Pulmonary 
alveolar macrophages); Cell sorting - flow cytometry; Epigenetic DNA methylation 
(Bisulfite sequencing); ELISA; DNA & RNA extraction; Electrophoresis; Real-time 
quantitative PCR; Egg & meat quality analysis; measuring carcass traits of chicken; 
SAS (statistic software); BISMA (Bisulfite sequencing DNA methylation analysis); 
Bio-Rad CFX96 (software for real-time quantitative PCR); DNAstar (primer design, 
DNA/protein sequences merge and align); Primer Premier / Methyprimer (primer 
design, DNA/protein sequences merge and align); FlowJo (flow cytometry) 
►Publication and contributions 
Thesis publication 
Yang Q, Pröll M, Salilew-Wondim D, et al. (2015): Lipopolysaccharide-induced 
expression of CD14 in TRIF pathway is epigenetically regulated by sulforaphane in the 
porcine pulmonary alveolar macrophages. Innate Immunity (Under review) 
Yang Q, Neuhoff C, Zhang R, et al. (2014): Sulforaphane inhibits CD14 gene 
expression in LPS stimulated alveolar macrophages of German Landrace pigs. The 
German Society for Animal Production Meeting (DGfZ/GfT). 17. / 18. Sep. 2014. 
Dummerstorf, Germany: A21 (Proc) 
Yang Q, Pröll M, Zhang R, et al. (2015): Lipopolysaccharide-induced expression of 
CD14 is epigenetically regulated by sulforaphane in pulmonary alveolar macrophages 
of German Landrace Pigs. The German Society for Animal Production Meeting 
(DGfZ/GfT). 16-17. Sep. 2015. Berlin, Germany: D14 (Proc) 
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Other publications 
Qiu MH, Yang Q, Wu HL, et al. (2011): Cloning and characterization of chicken 
ELOVL7 gene and comparison with other vertebrates. 5th International Conference 
Proceedings on Bioinformatics and Biomedical Engineering (iCBBE). 10-12. May 
2011. Wuhan, China. 
Yang Q, Jiang XS, Du HR, et al. (2009): Analyzing slaughter performance of different 
strains in the Daheng high-quality chickens, progress in China's poultry science. The 
14th Symposium Proceedings of National Poultry Science. 20. Jun. 2009. Haerbing, 
China. 
Yang Q, Liu YP, Zhu Q. The investigation of earthquake disaster reconstruction for 
layers in Anxian district, Sichuan Animal and Veterinary Sciences. 2009, (12):15-16.  
Ren WS, Zhu Q, Yang Q, et al. (2010): Analyzing of IMF and IMP different strains in 
the Daheng high-quality chickens. China animal husbandry and veterinary medicine, 
2011, (6): 230-232.  
Long YL, L DY, Yang Q, et al. (2011): Comparative analysis of meat quality and flavor 
in different strains of Daheng high-quality broiler. Journal of Sichuan Agricultural 
University. 2011, (2): 266-268. 
 
 
 
 
 
 
 
 
 
